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Abstract
Brand-name drug costs continue to create a burden for many US seniors who receive care
from healthcare institutions. Generic medication is as therapeutic as is brand-name drugs
and, in most cases, costs far less. Despite this cost difference, physicians continue to
prescribe brand-name drugs. The purpose of this cross-sectional study was to explore
physicians’ patterns of prescribing brand-name drugs over generic drugs. This study was
guided by the medical home model, which was developed in 1967 by the American
Academy of Pediatrics. The study incorporated a purposeful sampling approach with a
sample size of 151 physicians. Multiple linear regression was used to examine the
associations between cost of treatment using generic medications and determinants of
physicians’ pattern of prescribing brand-name medications over generic medications.
There were no statistically significant associations between physician belief of cost using
generic medications and determinants of physicians’ pattern of prescribing brand-name
medications over generic medications, suggesting that physicians’ prescription patterns
are not solely determined by cost of the drug to the patients. The positive social change
implication of this study is in the awareness that it generates among physicians, with
evidence to suggest the need for more education on the utility of generic drugs instead of
brand-name medications.
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Chapter 1: Introduction to the Study
Introduction
The cost of prescription drugs is too high for many in the United States. Because
of the high cost of prescription drugs, more people in the United States, including
children, are going without needed medications. According to Felland and Reshovsky
(2009), many people in the United States cannot fill their prescriptions due to the high
cost, and less favorable prescription drug coverage may also contribute to the high rate of
unfilled prescriptions. The most vulnerable individuals who continue to face these
challenges are the elderly, those with low income, and individuals without insurance
(Felland & Reshovsky, 2009). The cost of prescription drugs has become a policy issue
for the Medicare and Medicaid programs. At the state level, the debate has been driven
by increased Medicaid drug spending. Despite the issue of prescription drug cost,
researchers have not examined why physicians will not prescribe generic prescription
drugs when such equivalent generic brands exist.
The number of people in the Unites States under the age of 65 who were having
problems filling their prescriptions due to the high cost of prescription drugs was steady
in the early decade, but this trend changed. For example, the number of individuals
younger than 65 years of age who cannot afford their medication due cost grew from
10.3% in 2003 to 13.9% in 2007 for all (Felland & Reshovsky, 2009). About 36 million
people in the United States between the ages of 19 and 64 went without prescription
drugs because of cost in 2007; this was an increase of 11.7 million compared to 2003, and
unmet medication needs among working individuals rose from 13.8% to 17.8% between
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2003 through 2007 (Felland & Reshovsky, 2009). Medication under-usage was also a
common reported problem among the elderly with chronic health conditions such as
asthma, heart failure, hypertension, high cholesterol, depression, and diabetes (Piette,
Heister, & Wagner, 2004). Because children more likely to be in better health compared
to their elderly counterparts, they require fewer medications and have less prescription
access problems; however, unmet prescription medication needs grew between 2003 and
2007 from 3.1% to 5% (Felland & Reshovsky, 2009). It is possible that the increase in
prescription drug nonaffordability was a result of higher prescription drug cost, increased
use of brand-name drugs, and physicians not prescribing generic drugs. Furthermore, it
could be a result of drug prices rising faster than individual earnings and the introduction
of newer and more expensive medications in the marketplace.
The Medicare Modernization Act (MMA, 2003) is a voluntary program that helps
pay for prescription drugs through a private plan that is approved by the federal
government. According the Center for Medicare and Medicaid Services (CMC), there are
about 49 million individuals who have access to Medicare drug benefit programs [CMS],
2011). Public programs such as Medicare and Medicaid play a role in helping individuals
pay for their health care including prescription drugs, but continued increases in
prescription drug costs may make the program nonviable. There is also public concern
about the future of the prescription drug benefit program, particularly in light of the new
healthcare policy passed into law by the Obama administration, according to the
Congressional Budget Office [CBO], 2014). Seniors continue to be the largest users of
prescription medication: Those over 50 years of age use 64% of prescription drugs.
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Meanwhile, use of medications by people 19- to 25-years old went down. This change in
per-capita prescription drug use could be a result of better disease management or a trend
in self-rationing by patients, which could contribute negatively or positively to the future
healthcare costs in the US, according to Management Information System [MIS] (2011).
Problem Statement
Medication serves as a therapeutic intervention designed to manage both acute
and chronic health conditions. People in the United States who suffer from multiple
health conditions may depend on several medications to manage their health. Currently,
Medicare and Medicaid provide healthcare benefit for seniors through paying for some of
their healthcare costs including prescription drugs. However, out-of-pocket costs, higher
costs of prescription drugs, and the recent Medicare and Medicaid benefit reduction may
reduce the ability of seniors to meet this extra cost. Nursing homes may experience
difficulties in providing adequate care for their residents (CMS, 2012).The Health System
Change (HSC, 2003) revealed that many seniors in nursing homes take more than one
prescription drug to manage their chronic health conditions. According to Klein, Turvey,
and Wallace (2004), the elderly sometimes delay refilling their prescriptions due to high
costs. Being unable to refill a prescription could result in the individual not following
their medication regimen, which in turn can lead to further health problems and even
hospitalizations.
Chronic health conditions such as diabetes, hypertension, high cholesterol levels,
asthma, and depression require medications (Wood, 2012). According to Wood (2012),
high admission rates have been reported because of medication noncompliance and, in up
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to 33% to 69% of patients, the lack of medication compliance has resulted in up to
125,000 deaths per year in the United States . Cardiovascular disease is a chronic
condition associated with hypertension. In 2001, some 89,000 deaths would have
occurred among patients age 40 and older if blood pressure medications were not taken
(Wood, 2012). Patients who are diabetic are less likely to die prematurely if they adhere
to their medication regimen, and those who suffer from asthma are 11% less likely to
visit the emergency room (ER) or be hospitalized (Wood, 2012).
The New England Healthcare Institute (NEHI, 2009) reported that medication
noncompliance leads to a waste of dollars in the healthcare system. The NEHI further
revealed that most people in the United States do not take their medication as prescribed;
the resultant effect is an additional $100 billion yearly hospitalization costs, and the
barriers to medication compliance include the cost of prescription drugs (NEHI, 2009).
There is a correlation between poor health outcomes and patients who do not take their
medication as prescribed by their physicians. Among diabetic and heart-disease patients,
those who do not take their medication as prescribed had a higher mortality rate, 12.1%
versus 6.7% (NEHI, 2009). Additionally, among those who suffer from diabetes,
hypertension, high cholesterol levels, and poor heart conditions, the rate of
hospitalization is higher compared to those who take their medication as prescribed. In
addition, because 75% of US healthcare costs are tied to chronic disease due to
medication noncompliance, high prescription drug costs is a potential drawback to
improving health outcomes.
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Prescription drug spending continues to increase. In 2001, the cost of prescription
drugs in United State was $141 billion. Because seniors depend on Medicare prescription
benefit programs to offset some of their prescription drug costs, containing drug costs
could help to stabilize the Medicare program (Haas, Phillips, Gerstenberger, & Seger,
2005).
In 2007, yearly prescription drug costs in the United States reached $286 billion
(Paul et al., 2010). Generic drugs cost less when compared to brand-name drugs, so an
increased use of generic drugs could result in healthcare savings and serve as a costcutting strategy for nursing homes suffering from Medicare and Medicaid cuts. Several
expensive drugs will go off patent between 2010 and 2014. This will result in $209
billion yearly sale. If this trend continues, brand-name drug sales will see a further
reduction in yearly sales (Paul et al., 2010). Increasing or improving generic prescription
rates and reducing the sale of brand-name drugs can reduce healthcare costs and prevent
nursing homes from falling short in their revenues.
According to the Robert Wood Johnson Foundation (1996), chronic conditions
are the major cause of death among people in the United States, and almost 100 million
people in the United States suffer from some form of chronic health issue. It is projected
that by 2040, an estimated 160 million people in the United States will have a chronic
condition. The Robert Wood Johnson Foundation further revealed that the cost for caring
for people in the United States with chronic condition was $470 billion in 1995, and by
the year 2040, that cost is estimated to be $864 billion. According to Anderson (2004), in
2002, the United States 70% of all deaths were due to a chronic condition (i.e., heart
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disease, cancers, stroke, diabetes, mental illness, Alzheimer’s, kidney disease, and
respiratory diseases). In addition, 90% of seniors in the United States suffer from one
chronic disease, and 77% suffer from more than one chronic condition. According to
Mendelson, Ramchand, Abramson, and Tumlinson (2002), in 2002, nursing homes
residents received an average of 6.7 routing prescription drugs daily, with an additional
2.7 as-needed medications.
The cost of medications used to treat chronic conditions has social and economic
implications. For example, in 2008 one in five hospital admissions was a result of
diabetes, with total cost of $83 billion. Hospital stays of individuals with diabetes are
longer when compared to those without diabetes. Medicare covered 60% of the diabetes
cost, private insurance covered 23%, and the rest was covered by private payments
(Fraze, Jiang, & Burges, 2008).
Currently, state Medicaid programs provide healthcare services for people with
low incomes, long-term care for the older population and for individuals with disabilities.
As more chronic conditions become apparent, more people will need healthcare services,
and more will qualify for Medicaid benefits. In the state of North Carolina, there has been
an increase in the older population, with people having more chronic diseases. But with
recent Medicare and Medicaid budget cuts, there a need for new strategies in order for the
state to improve the quality of healthcare services and decrease healthcare costs (Kaiser
Health News [KHN], (2014)]. Medicare and Medicaid provide benefits for seniors to pay
for some of their healthcare costs, including prescription drugs. Any remaining balance is
considered an out-of-pocket cost and is the responsibility of the recipient (CMS, 2012).

7

The HSC (2003) revealed that many seniors take more than one prescription drug to
manage their chronic health conditions. The high costs of prescription drugs could eat
deeply into their low incomes and may prevent them from paying their Medicare and
Medicaid out-of-pocket costs including refilling their prescriptions (Strickland & Hanson,
1996). Nursing homes are revenue-driven organizations, and when residents run out of
money, two things may happen: they may be asked to go home without completing their
stay, or they may not have enough money to pay for their prescription drugs.
For example, paracetamol is a chemical ingredient found in brand-name
painkillers, but it is also sold as a generic drug. The Trade-Related Aspects of Intellectual
Property Rights (TRIPS) agreement does not prevent governments from requiring
accurate labeling or allowing generic substitution. Competition between drug companies
and generic producers has been more effective than negotiations with drug companies in
reducing the cost of drugs. The price of an average generic drug is 75% less than a brandname prescription drug (CBO, 2010).
The National Health Expenditure Accounts (NHEA) revealed that healthcare
spending reached $2.6 trillion in 2010. This is about $8,402 per person, and it is 18% of
the U.S. gross domestic product (CMS, 2012).The U.S government financed 29% of
healthcare costs in 2010, an increase from 23% in 2007. The NHEA also reported that
average yearly healthcare costs are expected to grow from 6.2% through 2018, a number
that surpasses the anticipated overall economic growth for the period of 4.1%. By 2018, it
is projected that national healthcare spending will reach $4.4 trillion (CMS, 2012). At this
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growth rate, in 15 years, healthcare costs will amount to 50% of U.S. GDP. The question
becomes whether or not the U.S. economy is sustainable with this amount of expenditure.
Prescription drugs are dispensed in hospitals, including long-term care facilities,
for the management of chronic diseases. Based on increasing healthcare costs, the use of
cheaper generic prescription drugs will hold down the growth of healthcare costs
nationally and across institutional settings such as hospitals and long-term care facilities.
The use of generic drugs saved the U.S. healthcare system about $1.07 trillion from 2002
through 2011, with $192.8 billion in savings in 2011 alone (CMS, 2012). Knowing that
the U.S. government’s share of healthcare spending will soon reach 30% and as the oldest
Baby Boomers become eligible for government-sponsored programs such as Medicare,
the increased use of generic prescription drugs is critical ensuring Medicare and Medicaid
sustainability (CBO, 2010).
Researchers have identified cost-saving approaches from various studies,
estimates that result because of the use of generic drug, and generic and therapeutic
substitutions. Other scholars have examined savings to the U.S. healthcare system and
savings from program implementations (CBO, 2010; Haas et al., 2005; Scott &
O’Donnell, 2007). The Generic Pharmaceutical Association (GPhA) estimated the
amount paid on generic drugs and brand-name drugs for the year 1999 through 2010 and
found that generic substitution saved the U.S. healthcare system about $1 trillion. In 2010
alone generic substitutions saved the U.S. healthcare system more than $157 billion
(GPhA, 2011). The CBO (2010) examined savings that resulted because of the use of
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generic drugs in the Medicare Part D prescription drug program and found that it resulted
in a cost saving of $33 billion in 2007.
The CBO (2010) evaluated additional savings from generic and therapeutic
substitutions and found that an increase in generic substitutions at the rate of 100% would
have resulted in cost savings at about $900 billion and an additional cost savings of $4
billion in therapeutic substitutions in 2007. Scott and O’Donnell (2007) analyzed cost
savings through program implementation in a managed-care organization in the form of
physician participation in 2005 and 2006 and found that after program costs, the
organization saved $397,486 in 2005 and $453,545 in 2006. Dobscha, Winterbottom, and
Snodgrass (2007) conducted a study for the Department of Veterans Affairs (VA)
hospital and found potential savings through program implementation of promoting the
use of generic antidepressants over brand-name medications. From March of 2002
through August, the policy resulted in a net saving of $2.5 billion (Dobscha et al., 2007).
Two scholars used data regarding claims from 45 private health insurance
organizations from 2003 through 2007 to compare the cost of health care in individuals
using selective serotonin reuptake inhibitors ( SSRI) when therapeutic substitution
occurs midtreament. Wu et al. (2011) found that patients who switched from brand-name
drugs to generic drugs had higher rates of hospitalization due to switching in
midtreatment. The switch also result in healthcare cost savings of $881 dollars (Wu et al.,
2011). Viahiotis, Devine, Eicholz, and Kautzner (2011) used claim data from 2005 to
2007and compared healthcare costs of using brand-name drugs versus generic drugs in
midtreament for 6 months. The conclusion was that the cost of generic antidepressant
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SSRIs was significantly lower when compared to brand-name medications (the average
was $3,660 and $4,587, respectively) (Viahiotis et al., 2011).
Significance
Concerns have been raised about the rise in prescription drug spending, the cost of
diabetes, and Medicare and Medicaid expenditures. These factors influence Medicare and
Medicaid spending with respect to hospital and nursing home funding. Nursing home
expenditures are a financial burden for those who receive treatment, and particularly for
those who are not covered by Medicare and Medicaid. The CBO (2010) reported that in
2007, dispensing generic drugs rather than brand-name drugs reduced prescription drug
costs by $33 billion. The American Diabetes Association (ADA, 2013) revealed that in
2012, the total estimated cost of diagnosed diabetes was $245 billion, including $176
billion in direct medical costs and losses to productivity of $69 billion. In patients with a
chronic medical condition such as Type 2 diabetes, intensive blood glucose control with
prescription drugs may decrease the progression of microvascular disease and prevent
heart attacks. However, the cost of prescription drugs may inhibit this treatment (ADA,
2013).
Generic prescription drugs are therapeutic and serve the same purpose as brandname drugs, but they are less expensive when compared to brand-name drugs. The
United States Food and Drug Administration examines generic drug formulation and if it
finds them to be suitable, will approve them as therapeutically equivalent to brand-name
drugs in terms of safety, strength, and quality (as cited in Haas et al., 2005). Substituting
generic drugs for more expensive brand-name prescription drugs will provide savings for
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the drug-consuming population (Haas et al., 2005). Due to the rising cost of healthcare
stemming in part from the cost of prescription drugs and the cost of managing chronic
health conditions, healthcare policy makers can no longer ignore….Many depend on
Medicare and Medicaid for healthcare services, and sustaining these social programs is
critical in addressing healthcare costs. The increased use of generic prescription drugs
through physician automation generic prescription is critical to ensuring Medicare and
Medicaid sustainability.
The results of this study can lead to positive significant social change by
providing patient education on potential savings from generic medication and by
providing information on how generic drugs are cheaper and are therapeutically
equivalent as brand-name drugs. The time required for generic entry into the U.S. market
is too long. This has a significant negative implications on pharmaceutical expenditure.
The knowledge gained from this study can be used to reverse this trend. The use of
generic drugs is a policy option that will allow for access to affordable drugs. The
knowledge gained from this study can also be used to address negative perceptions of
generic drugs. If patients have a positive perception of generic drugs, they may be
prompted to use more generic drugs or to ask their physicians to prescribe generic drugs,
making it easier for them to afford to pay for their medication. Through generic
substitution savings, more money will be available to increase the primary prevention
aspects of care. Finally, this study will provide policy makers with relevant information
that will aid in their decision-making process. Because Medicare and Medicaid cuts are a
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challenge to seniors, the information gained from this study can serve as a strategic tool
in the area of generic cost savings.
Purpose of the Study
This study used a quantitative research approach. The purpose of this study was to
address the behavior of primary care physicians regarding the prescribing of generic and
brand-name drugs for the treatment of chronic conditions in the state of North Carolina.
Although government programs such as Medicare and Medicaid provide health benefits
to millions of people in the United States, including prescription drug benefits, recent
cuts in these programs and the cost of prescription drugs continue to impact beneficiaries
of these programs, including those in North Carolina (KHN, 2014).
Theoretical Framework
The theoretical framework of this study was based on the medical home model
concept that was presented in 1967 by the American Academy of Pediatrics. The medical
home model is characterized by the availability of a personal physician for every
family/patient. The delivery of first-contact care is ensured by the physician in this
model. Understanding of the needs of the family/patient and facilitation of
comanagement that is planned throughout the individual’s lifespan is also made certain
by the physician. The physician must have the capacity and resources to fulfill the needs
of the family/patient (Health Policy Brief, 2010).
The basis of this model resides in the delivery of patient-centered care that
involves a team-based approach for facilitating a complete range of healthcare services.
This includes the provision of care to all age groups and at all the stages of chronic care,
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acute care, mental and behavioral health care, end-of-life care, and preventive services. It
also involves the coordination and integration of care that is not delivered by the PatientCentered Medical Home Model (PCMH) across the multifaceted healthcare system and
patient community. The emphasis of this model is on the reduction of the costs of care by
improving access to vigorous primary care. The medical home model presents a way to
improve health care in the United States through the transformation of the process of
organization and delivery of primary care, according to Consumer Assessment of
Healthcare Providers and System (CAHPS, 2011). This framework is of value for the
provision of care by primary care physicians practicing in Raleigh, North Carolina. It
forms the basis for the prescription of appropriate drugs that can be more affordable in
order to ensure that the population is receiving adequate care in accordance with the
guidelines of the medical home model concept.
This theoretical framework was selected because it provides an approach towards
integrative health care that, in this model, is based on one main point of access. Most of
the healthcare systems in the United States are using this model of health care for
providing services to patients. Data can be retrieved through this model regarding the
prescribing practices of primary care physicians in the state of North Carolina. Several
scholars have used this model (Henderson, Princell, & Martin, 2012; Jaudes et al., 2011).
Lee et al. (2011) used this model to determine the possibility of eliminating disparities in
health care that are encountered by minorities in accessing healthcare services. Windel,
Anderko, and Konetzka (2011) claimed that this model can be employed for shared
decision making that can be useful in supporting the choices of patients regarding the
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prescription of drugs. Shared decision making ability permits the patient to be involved in
selecting the most appropriate type of drug that is best from all aspects. This model can
also curb the cost of health care through the use of medicines that are preventative and
cost effective (Marshall et al., 2011). Therefore, this model was used as a theoretical
framework in this study because it can facilitate the use of generic medicines.
The medical home model can also be applicable to the healthcare needs of seniors
residing in nursing homes. Just as geography, transportation, and financial barriers impact
children, these barriers also affect seniors in nursing homes across the United States. The
model is designed so that patients, including seniors in nursing homes, get care when and
where they need it (National Committee for Quality Assurance [NCQA], 2011). Using
the medical home model provides a template for providing care for seniors residing in
nursing homes in North Carolina.
Research Question
This study included the following research question:
1.

What factors influence physicians’ patterns of prescription of brand-name
medications over generic medications?
Hypotheses

H1: Brand popularity and its therapeutic effect do not influence prescribing
behavior of brand-name medications over generic medications.
H0: Brand popularity and its therapeutic effect do influence prescribing behavior
of brand-name medications over generic medications.
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Nature of the Study
This study was quantitative in nature. I examined the behavior of physicians
regarding the prescribing of generic and brand-name drugs for the treatment of chronic
conditions in North Carolina.
Study Limitations
There were several limitations associated with this study. First, I was required to
conduct the surveys in a predetermined period of time. Second, the sample of the study
included only the population of North Carolina. Therefore, the results of this research
were representative of only a specific region and might not be applicable to the entire
population of the United States. The sample size of the study was also a limitation
because it was too small to represent the practices of all the general practitioners
regarding the prescription of generic and brand-name drugs. Another limitation of this
research was the method of data collection in that an online survey was used. This
method did not produce a large enough sample size. This can cause difficulties in the
statistical analysis of the data. Quantitative studies using a statistical analysis method
require a large sample size to provide valid results. Based on this fact, there will be a
need for further research with a larger sample size to ensure the development of valid
results.
Summary
The cost of prescription drugs poses a challenge for millions of people in the
United States, and also presents a cost-control challenge for private and public health
organizations. Because of the high cost of prescription medications, more people in the
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United States are going without prescribed drugs. According to Felland and Reshovsky
(2009), one in seven individuals under the age of 65 in the US was not able to fill their
prescription drug as a result of cost. The high cost of medication and less favorable
prescription drug programs may contribute to the high rate of unfilled prescriptions. The
elderly are the most vulnerable individuals who continue to face these challenges because
most of them lack insurance and are on low or fixed incomes (Felland & Reshovsky,
2009). Several researchers (CBO, 2010; Haas et al., 2005; Scott & O’Donnell, 2007)
indicated that generic drugs are therapeutic and cost far less when compared brand-name
drugs, and significant cost savings can result with increased use of generic medications.
Reports also indicate that the elderly delay refilling their prescriptions due to cost.
The elderly saw their prescription drug cost jump from $28.50 in 1992 to $42.30 in 2000
while the number of prescriptions written is steadily increasing (Korn, Reichert, Simon,
& Halm, 2003).The impact of not being able to refill prescription drugs as a result of
cost could lead to non-medication compliant. Medication noncompliance has been
shown to result in repeat hospitals visits. In 2001, the cost of prescription drugs in the
United States was $141 billion. Since seniors depend on social programs such as the
Medicare prescription benefit to offset some of their prescription drug costs, containing
drug spending costs could stabilize the Medicare program. There is a need for educating
patients, healthcare professionals, policy makers, and physicians to make them more
aware that greater prescription of generic drugs can save money. Chapter 2 will focus on
the literature review, a brief history of Medicare and Medicaid, brand-name drugs versus
generics, and cost differences.
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Chapter 2: Literature Review
Introduction
The rise in prescription drug costs, particularly for brand-name prescription drugs,
is concerning to many people in the United States, including private and public health
institutions. This cost is a central policy issue for the Medicare and Medicaid programs.
At the state level, the debate has been driven by increases in Medicaid drug spending.
Despite the continued rise in prescription drug costs, little research has been conducted
concerning why physicians will not automatically prescribe generic drugs considering the
relative low cost of generic medication as compared to brand-name prescription drugs.
State awareness of prescription drug spending in nursing homes has also increased as
budget challenges force Medicaid cost-containment strategies. At the same time, the
elderly population is increasing in the United States, and this growing population has
chronic health conditions. Most of this older population depends on nursing homes for
their healthcare needs (Mendelson et al., 2002). In 1997, for example, there were about
1.6 million residents in 17,000 nursing homes across the United States (author, year).
This number will continue to increase as a result of the growing older population
(Mendelson et al., 2002). In 2002, nursing home residents received an average of 6.7
routing prescription drugs daily, with an additional 2.7 as-needed medications. The
number of medications prescribed in nursing homes increased by 14% in 2000.
The aging of the Baby Boomer generation is predicted to increase the percentage
of people over the age of 75, a cohort that was 5.8% of the population in 1997 and is
expected to account for 9.4% in 2025. Also, advances in medical technology will allow
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more people to live longer (sometimes with less social support) and there are presently
not enough nursing homes to care for the elderly population. According to NCCPPR
(2013), the elder population in the state of North Carolina will double in 2030, increasing
from 1.1 million to 2.2 million. The Medicaid program will take up more portions of the
state budget. Currently, the state Medicaid program provides healthcare services for
people with low income, long-term care for the older population, and care for individuals
with disabilities. As this growth continues, the state will need spend more on nursinghome services because more people will qualify for Medicaid benefits. Is the state of
North Carolina ready for this population growth, particularly with recent Medicare and
Medicaid budget cuts? Or are there strategies the state can employ to improve the quality
of healthcare services and decrease or at least control healthcare spending?
Other components that affect the Medicare and Medicaid budgets include the cost
for managing chronic diseases such as diabetes, cardiovascular disease, cancer, and
asthma. For example, according to the CDC (2011), 23 million children and adults in the
United States—about 8% of the population—suffer from diabetes. About 25% of the U.S
population age 60 and older have diabetes, and it is estimated that by the year 2050, 48
million U.S. residents will be diagnosed with diabetes (CDC, 20011). About 107 million
people in the United States suffer from some form of chronic illness, and seven of 10
people die from chronic disease every year. Heart disease, cancer, and stroke constitute
the major share of these conditions, contributing to about 50% of all deaths each year
(CDC, 2011). The cost of one chronic disease, diabetes, as reported by the ADA (2013),
was $245 billion in 2012, including $176 billion in direct medical costs, and losses in
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productivity amounting to $69 billion. The components that make up those diabetes
medical expenditures include hospital in-patient care, which is 43% of total medical care;
prescription drug to manage diabetes, which is 18%; and diabetic agents and other
medical supplies, which account for 12%. Physician office visits are 9% and nursing
homes/ residential facility stays are 8% (ADA, 2013). An increased understanding the
economic consequences of diabetes and its determinants could help policy makers at both
the state and federal levels to find ways to reduce healthcare spending. Heart disease,
cancer, asthma, diabetes, and hypertension are among the five most costly chronic
conditions in the United States. They cost the country about $347 billion in 2010, which
is about 30% of total healthcare costs (CDC, 2011). The number of individuals
diagnosed with Alzheimer’s in the United States is increasing. It is reported that by 2050,
the number of Alzheimer's cases will reach 16 million (CDC, 2011). This trend will
impact Medicare spending; in fact, in 2005 Medicare paid $9 billion for individuals
diagnosed with Alzheimer’s; by 2015, it was expected to reach $189 billion (CDC, 2011).
The CDC (2011) reported that it costs the United States approximately $74 billion
to care for a cancer patient (a treatment with Avastin costs more than $90,000 for a 1.5
month period), and Medicare paid $7.3 billion on in-patient cancer care (CDC, 2011).
Because chronic diseases account for much Medicare spending, any increase in the
number of chronic conditions will impact the Medicare budget. Medications can help
manage acute and chronic health conditions, and many older adults depend on several
medications to help them manage health effectively. The current Medicare and Medicaid
programs provide benefits for seniors, including those in nursing homes, to pay for some
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portion of their healthcare costs including prescription drugs. The remaining balance is
considered out-of-pocket cost and is the responsibility of the recipient (CMS, 2012). The
HSC (2003) revealed that many seniors in nursing homes are on low and/or fixed
incomes and take more than one prescription drug to manage their chronic health
conditions. Considering the high costs of prescription drugs, those with fixed and low
incomes may find it difficult to pay for their Medicare and Medicaid out-of-pocket costs,
including refilling their prescriptions (Strickland & Hanson, 1996). Medication is an
essential aspect of managing chronic diseases, particularly for the elderly. Because social
programs such as Medicare do not cover all aspects of prescription drugs, the elderly
have difficulty affording drugs (Reed, Hargraves, & Cassil, 2003).
Prescription drug costs are a burden for African Americans, as researchers have
found that among African Americans age 65 and older, those using Medicare find it
difficult to fill their prescriptions (Reed et al., 2003). The increase in chronic conditions,
low income, and a lack of supplementary insurance explain the prescription access gap
that exists between older African American and their European American counterparts
(Reed et al., 2003). According to Reed et al. (2003), chronic conditions such as heart
disease, high blood pressure, and diabetes are common among older African Americans,
and they require prescription drug management. Additionally, complications that can
result from diabetes such as renal failure, blindness, and gangrene because of lack of
medication compliance can be avoided through proper prescription drug regimens (Reed
et al., 2003).
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According to Klein et al. (2004), the elderly sometimes delay refilling their
prescripts due high costs. Not taking medication as prescribed can have health
consequences; it could lead to further decline in health, result in repeated visits to the
hospital, and may increase the number of days that the patient must stay in a nursing
home. Beside the cost impact on individuals, prescription drug costs also impact other
segments of society. In 2001, the cost of prescription drugs in United States was $141
billion. Because seniors depend on Medicare prescription benefit programs to offset some
of their prescription drug cost, containing drug costs could stabilize overall Medicare
program costs (Haas et al., 2005). Generic prescription drugs are considered therapeutic,
serve the same purposes as brand-name drugs, and are less expensive when compared to
brand-name drugs. The United States Food and Drug Administration examines generic
drug formulations and, if it finds them suitable, approves them as therapeutically
equivalent to brand-name drugs in terms of safety, strength, and quality (Haas et al.,
2005). According to Haas et al. (2005), substituting generic drugs for the more expensive
brand-name prescription drugs would provide savings for the drug-consuming
population.
Medicare and Medicaid are two social programs designed to provide medical
support for many Americans, including the elderly. The demand for these programs will
continue to increase because as the population grows, the increase in chronic conditions
grows as well. As this trend continues, the nation and the individual states will continue
to be challenged to find new ways to minimize costs while at the same time delivering
quality of care. Promoting a comprehensive Medicare prescription drug benefit plan that
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incorporates automatic physician prescription of generic drugs will close the access
prescription drug gap that exists between elderly American Blacks and their White
counterparts, and it will further more create savings for nursing homes including those in
North Carolina.
In preparing this literature search, sources such as MEDLINE, CINAHH, Walden
Library, Book, and CDC, ADA, FDA websites, including some nonpeer-reviewed
articles were used to maximize search effectiveness while minimizing extraneous results.
The following words were used in retrieving the relevant documents: Full text, HTML,
Boolean methods, PROQUEST, EBSCO, and SAGE Full-Text.
Articles that meet the following criteria were utilized for the literature review: (a)
the study has bearing on the current research been undertaken, (b) full-text copy that
includes a detailed description of the study including study design and methodology, and
(c) the publication or article is written in English. The information obtained from the
articles, books, and web sources are addressed and summarized in the following sections
within Chapter 2 of the Literature review. In the first two sections, chronic health
conditions including diabetes and conditions that require treatment with medications are
presented. Diabetes is included in the discussion because it is considered a chronic health
condition, and many seniors who are residents of nursing homes including those in North
Carolina suffer from diabetes. In the third section, a historical perspective of the
Medicare and Medicaid system is presented, and in the fourth section, the drug approval
process, the costs of brand-name prescription drugs and generic drugs are presented. And
in the fifth section, brand-name prescription drug and generic prescription drug
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affordability, costs to organizations and costs to individuals are presented. The sixth
section includes a chapter summary.
Theoretical Framework
The theoretical framework of this study will be based on the medical home model
concept presented in 1967 by the American Academy of Pediatrics. The medical home
model is characterized by the availability of a personal physician for every family/patient.
The delivery of first-contact care is ensured by the physician in this model.
Understanding of the needs of the family/patient and facilitation of co-management that
is planned throughout the lifespan is also made certain by the physician. The physician
must have the capacity and resources to fulfill the needs of the family/patient (Health
Policy Brief, 2010).
The basis of this model rests on the delivery of patient-centered care that involves
a team-based approach for facilitating a complete range of healthcare services. This
includes the provision of care to all the age groups and at all stages including chronic
care, acute care, mental and behavioral healthcare, end-of-life care, and preventive
services. It also involves the coordination and integration of the care that is not delivered
by the PCMH across entire fundamentals of the multifaceted healthcare system and
patient community. The emphasis of this model is on the reduction of the cost of care by
improving access to vigorous primary care. A promising way is represented by the
medical home model for improving healthcare in America through the transformation of
the process of organization and delivery of primary care (CAHPS, 2011). The medical
home model is important because it provides guidance for physicians following the
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medical home model. Within this model, the primary care physician would be able to
provide treatment while bearing the mind the affordability of the prescribed drug for the
family/patient.
This theoretical framework has been selected because an approach is provided
towards integrative healthcare by this model that is based on one main point of access.
Most of the healthcare systems in the US are utilizing this model of healthcare for
providing services to patients. An enormous amount of data can be retrieved through this
model regarding the prescribing practices of primary care physicians in the state of North
Carolina in Raleigh, and thus provide a better opportunity towards initiation of change in
the practices of primary care physicians pertaining to their prescription practices. There
are several studies that have utilized this model (Henderson et al., 2012; Jaudes et al.,
2011). Lee et al. (2011) utilized this model to determine the possibility of elimination of
disparities in healthcare that are encountered by the minorities in accessing the healthcare
services. Windel et al. (2011) described the benefits of this model as it can be employed
for shared decision making that can be useful for supporting the choices of patients in the
prescription of drugs. Shared decision making permits the patients to be involved in
selecting the most appropriate type of drug that is best for them from all aspects. This
model can also help to curb the costs of healthcare through the utilization of medicines
that are better preventatives and are more cost effective (Marshall et al, 2011). Therefore,
this model has been utilized as a theoretical framework of this study because it can
facilitate the utilization of generic medicines.
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Cost of Chronic Conditions
A chronic condition is a repeating health consequence that affects individual daily
life, and it may last for several years (Anderson & Horvath, 2004). There is currently no
cure for many chronic health conditions, but they can be managed adequately with
medication. Chronic conditions are costly and tend to afflict the elderly population. It is
estimated that more than 70 million Americans age 50 and older suffer from one type of
chronic health condition, diabetes is one of them. According to the Robert Wood Johnson
Foundation (1996), chronic conditions are a leading cause of death, and almost 100
million Americans suffer from some form of chronic health issue. The projection is that
by 2040 an estimated 160 million Americans will have a chronic condition of one sort or
another. According to Anderson (2004), in 2002 in America 70% of all deaths in 2002
were attributed to a chronic condition such as heart disease, 90% of seniors in America
suffer from one form of chronic health condition, and 77% suffer from more than one
chronic condition.
Long-term care includes nursing home facilities. Nursing homes provide care to
an increasing number of U.S. elderly persons who suffer from several chronic health
condition including diabetes. A study conducted by Resnick, Heineman, Stone, and Shorr
(2004) collected data on 11,939 from nursing home residents aged between 65 years
representing 1.32 million individuals. In their study they found that in 2004, 24.6% of all
nursing home admissions were suffering from diabetes at the time of admission. Also,
those admitted with diabetic complications tended to be admitted from acute-care
hospitalizations (42.5% of such admissions, compared to only 35.5% for other non-
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diabetic patients), and those admitted with diabetic complications typically had longer
stays in the facility than non-diabetic patients.
A similar study conducted by Johnson, Brosseau, Soul, and Kolberg (2008) made
the following observation about chronic diseases such as Type 2 diabetes: it affects 190
million people globally, and it is reported that this number is expected to increase to 300
million by 2025. Their study further revealed that patients residing in long-term care
facilities often suffer from more than one chronic disease, with 25% suffering from
diabetes, 80% suffering from cardiovascular disease, 56% suffering from hypertension,
and a total of 69% of patients suffering from more than one chronic condition. The cost
of managing chronic diseases has been a major concern for healthcare professionals
because patients who suffer from multiple chronic diseases take more than one
medication to manage their chronic conditions, and the high cost of prescription drugs is
an issue.
According to the American Diabetes Association (ADA, 2007), in 2007 there
were 17.5 million people with diagnosed diabetes with an estimated cost of $174 billion
in direct medical costs and indirect costs through lost productivity. A second study
conducted by the ADA in 2013 that used a prevalence-based approach reported that the
economic burden due to diabetes in the US in 2012 was $245 billion—a 41% increase
compared to the previous study. The components that make up those diabetes medical
expenditures include hospital in-patient care (43% of total medical care), prescription
drugs to manage complications associated with one of the chronic condition, diabetes was
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18%, antidiabetic agents and other medical supplies account for 12%. Physician office
visits 9%, and finally nursing homes/ residential facility stays 8% (ADA, 2013).
Murray and Callahan (2003) concluded in their study that American adults age 50
and above suffer from multiple chronic diseases and require more than one medication to
manage their chronic condition. A research study conducted by DeVol and Beddroussian
(2007) for the Milken Institute revealed that in 2003 treatment cost for seven chronic
diseases totaled $277.7 billion. Treatment costs were highest for heart disease, at $64.7
billion; for five leading cancer treatments, the combined cost was at $48.1 billion; mental
health disorders reached a total treatment cost of $45.00 billion; pulmonary conditions
cost $45.2 billion; hypertension came in at $32.5 billion; diabetes was at $27.1 billion,
and stroke accounted for $13.6 billion.
Klonoff (2008) reported that the cost of prescription drugs is on the rise,
particularly for diabetes medications. His study revealed that as of 2007, treatment of
diabetes become the leading source of increased spending on prescription drugs. The
CDC (2009) revealed that approximately $7,900 was spent in 2009 to manage chronic
conditions, this will translate into $3 out of every $4 spent on the nation’s healthcare. The
agency further revealed that it cost $432 billion per year to treat heart disease and stroke,
while lung disease cost $ 154 billion per year, and Alzheimer’s disease cost $148 billion
per year. The long-term effects of chronic diseases add to suffering and chronic pain, and
unfortunately many Americans in this situation continue to face rising healthcare costs
while in many cases access to care is limited. The financial burden on individual, families
and on society as a result of chronic disease can no longer be tolerated.
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There are several components that contribute to healthcare cost. These include the
high cost of prescription drugs and the cost it takes to manage chronic diseases such as
diabetes. The Robert Wood Johnson Foundation (1996) found that the cost of caring for
Americans with chronic conditions was $470 billion in 1995, and by the year 2040 that
cost is estimated to reach $864 billion.
The share of Medicare beneficiaries with more than one chronic condition
increased from 30% in 1987 to 50% in 2002 (Thorpe & Howard, 2006). Chronic
condition management varies by treatment, its cost is a burden to society, and it affects
public programs such as Medicare and Medicaid. Holahan, Schoen, and McMorrow
(2011) reported that it cost the U.S. public health programs about $635 billion in 2010 to
manage chronic illness: This is about 30% of total U.S. healthcare spending, and nearly
half of that $635 billion–an estimated $304. 5 billion–was spent on beneficiaries of
Medicare and Medicaid.
The ADA’s 2007 report also revealed that a total of 168 million inpatient hospital
days in the U.S was attributed to one chronic condition alone, diabetes and an estimated
one-third of all nursing days stay was attributed to diabetes. Increased understanding of
the economic consequences of diabetes and its major determinants will help policy
makers at both the federal and state levels to formulate polices that will address the
prevalence of diabetes and its associated economic burden. Since most hospitals, nursing
homes, and the elderly depend on Medicare and Medicaid program payments and
benefits, current reductions in Medicare and Medicaid payments mean that proper
management of diabetes in the hospital and nursing home settings may be in jeopardy.
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Heart disease, cancer, asthma, diabetes, and hypertension are among the five
leading most costly chronic conditions in the US. Together, these cost the country about
$347 billion in 2010, or about 30% of total healthcare spending (CDC, 2011). The
number of individuals diagnosed with Alzheimer’s in the US is increasing, and it is
predicted that by 2050 the number of Alzheimer’s cases will reach 16 million (CDC,
2011). This trend will greatly impact Medicare spending. In fact, in 2005 Medicare paid
$9 billion for care of individuals diagnosed with Alzheimer’s; by 2015 it will reach $189
billion (CMS, 2005).
Chronic Condition Treatments
Prescription drug cost is a major concern to so many Americans and it plays a
major role in managing ill health. According to Reed et al. (2003), chronic conditions
such as heart disease, high blood pressure, and diabetes that are very common among
older Black Americans can be managed effectively with prescription drugs.
Additionally, complications that can result from diabetes such as renal failure, blindness,
and gangrene can be avoided by following a proper prescription drug regimen (Reed et
al., 2003).
Besides prescription drug costs, there are other components that impact healthcare
costs. These include chronic conditions such as cardiovascular diseases, cancer, and
diabetes. State government also feels the cost of ill health as a result of chronic
conditions, and without some form of an aggressive intervention these rising cost trends
will continue. The issue of pharmaceuticals can play a major role. According to the
Agency for Healthcare Research and Quality (ahrg, 2005), in the US the prevalence of
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diabetes continues to rise, it disproportionally affects the elderly, and it is higher among
racial and ethnic minorities. Type 2 diabetes can be managed effectively with diet and
oral diabetes medications. Data from a randomized controlled trial demonstrated that the
risk of retinopathy can be reduced by improving glycemic control in individuals suffering
from Type 2 diabetes (ahrg, 2005).
The two types of drugs use in treating Type 2 diabetes in 1995 were sulfonylurea
and insulin. However, there are many more new pharmacotherapy options available
today. Currently in the US there are 11 classes of diabetes prescription drugs, including
biguanides (i.e., metformin), thiazolidinediones, sulfonylureas, dipeptidyl peptidase-4
(DPP-4) inhibitors, meglitinides, glucagon-like peptide-1 (GLP-1) receptor agonists,
amylin analogue, bromocriptine, alpha-glucosidase inhibitors, colesevalam (a bile-acid
sequestrant), and insulin (ahrg, 2005). All of these drugs work differently, and it was
reported that between 1999-2000, about 6% of Type 2 diabetic patients were taking only
three classes of medication, as compared to 2005 - 2006 when 35% of such patients take
two classes of antidiabetes medication and 14% take three or more classes (Ahrg, 2005).
American adults within the age of 50 years and above suffer from multiple
chronic health conditions and require more than one medication to manage their chronic
health condition (Murray & Callahan 2003). According to Murray and Callahan (2003),
the use of medications including diabetes medications has several benefits: it improves
quality of life, preserves cognition and physical functioning, reduces economic burden on
society, and reduces the risk of additional comorbidity and eventual death.
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Better management of diabetes that includes the use of diabetic agents is critical
in reducing the economic burden presented by this disease; however, the cost of
prescription drugs in its treatment is an issue. According to Klonoff (2008), in 2007
diabetes medication accounted for 7% of prescription drug spending. Medco in 2007
reported that diabetes medication is number one as a top therapeutic category
contributing to increased drug spending in the US (Klonoff, 2008). Future diabetes drug
cost trend will be affected by new approved drugs, and the predicted prevalence increase
in diabetes will increase drug utilization and thus drug costs. Generic prescription drugs
are effective in the management of chronic diseases including diabetes because they have
almost the same components as the brand-name prescription drug and cost less (Klonoff,
2008).
Heart disease can cause death in men and women. Hypertension, high levels of
cholesterol, obesity, and diabetes are known to be complications associated with heart
disease. A daily dose of aspirin can prevent heart disease, and statin medications are
known to lower cholesterol levels. Hypertension can be managed with a combination of
drugs; they include angiotensin converting enzyme (ACE) inhibitors, water pills or
diuretics, beta-blockers, and calcium channel blockers.
There are two class of chemotherapy drug for treating cancer; they include
alkylating agents and antimetabolites. Chemotherapy drugs such as alkylating agents
work by damaging the DNA of the target cells and thus preventing reproduction; they are
used to treat leukemia, lymphoma, Hodgkin’s disease, cancer of the breast, and lung
cancer. Antimetabolites work differently. This class of drugs interferes with DNA and
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RNA growth by the process of substitution. They are used to treat leukemia, cancer of the
breast and ovarian cancer.
Historical Perspective of Medicare and Medicaid
The Social Security Act of 1965, commonly referred to as Title XVIII, was
implemented to provide health insurance benefits for the aged and the disabled persons.
The Act was later amended in 1966 to provide coverage for persons age 65 and older
through the Medicare payment system (Stephen & Torrens, 2002). Medicare is a
federally sponsored program, while Medicaid is a partnership program between the
Federal government and the states. Both programs provide meaningful support for and
play a crucial role in the U.S. health delivery system. Hospitals and nursing-home
residents who need special services with chronic health conditions depend on Medicare
and Medicaid for insurance benefits. With increases in the U.S. elderly population as a
result of the baby boomer generation, increases in chronic health conditions and recent
reductions in both programs, those that depend on these programs may have to come-up
with additional out-of-pocket fees to cover for needed medical services.
Medicaid
After much debate from Congress, the legislation to establish Medicare and
Medicaid program under Title XVIII and Title XIX was enacted into law in 1965
(Stephen & Torrens, 2002). Medicaid was established as a public response to the lack of
medical care available under public assistance. Both programs were originally managed
by the Department of Health, Education, and Welfare; in 2002, the duties of both
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programs were transferred to the Center for Medicare and Medicaid Services (Stephen &
Torrens, 2002).
Title XIX was established as the Medical Assistance program and it was later
known as the Medicaid program which was expanded through the Kerr-Mills Medical
Assistance program for the aged (Stephen & Torrens, 2002). Funding for Medicaid is
supported by the federal government and administered by the states, eligibility for
Medicaid is limited to low-income individuals and families. Title XIX of the Medicaid
program mandates the states to provide the following basic health related services:
hospital in-patient care, hospital outpatient services, nursing home care for those age 21
and older, diagnosis, laboratory, and X-ray services. Additional services under the
program include a prescription drug benefit, and physician services.
Healthcare spending in the U.S. saw significant growth over last few decades. For
example, in 1960 it was $27.5 billion, and in 1993 it was $912.6 billion with an average
increases of 11.2% yearly (CMS, 2007). While healthcare spending saw a decline of a
relatively small amount in the years 1993 to 1999, it picked up in the years between 1999
and 2002, rising 7.0% in 2000, 8.6% in 2001, and 9.1% in 2002. As a share of gross
domestic product (GDP), healthcare spending in the US rose from 13.8% of GPD in 2000
to 16.0% in the year 2005. For the number of 297 million residing in the U.S, average
healthcare expenditure in the year 2005 was $6,697 per individual (CMS, 2007).
The largest share of healthcare spending for the US under the CMS comes from
Medicare, Medicaid, and the State Children’s Health Insurance Program (SCHIP).
Altogether these cost the U.S government an estimated $661 billion in 2005 (CMS,
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2007). Since the implementation of Medicare and Medicaid programs, there have been
many legislative initiatives and public outcries to make changes that will help the
nation’s aged, disabled, and disadvantaged.
Medicare
Title XVIII was known as the Social Security Act of 1965, and it was designed as
a health insurance program to help the aged and the disabled. This program is now called
Medicare (Stephen & Torrens, 2002). First implemented in 1966, Medicare provides
coverage for individuals age 65 and older, and in 1973 railroad retirees and individuals
with end-stage renal diseases (ESRD) became eligible.
Medicare when it was first designed contained two components: A part known as
the Hospital Insurance (H1), or part A; and the other part is called the Supplementary
Medical Insurance (SMI), or part B. Part A provides for in-patient hospitalization, home
health, skilled nursing facility care, and hospice care. Part B, the Supplementary Medical
Insurance component, covers physician services, home health care, outpatient
hospitalization, and other services. Part B eligible patients pay a premium (Stephen &
Torrens, 2002). There is a third component to the Medicare program—Part C, the
Medicare Advantage program. This program was established under the Medicare
+Choice program by the Balanced Act of 1997. This program later become the Medicare
Prescription Drug, improvement, and Modernization Act (MMA) that was enacted into
law during the Bush Administration.
Since 2006, the MMA program provides prescription drug insurance coverage at a
subsidized rate to eligible persons, and also gives individuals the freedom to participate in
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private health insurance plans. Since July 1, 1996, those enrolled in the Medicare
program total 19 million that number grow to over 44 million in 2007 for both Part A and
Part B Medicare programs, and about 8 million for the Medicare Advantage plan. In the
year 2006, Part A Medicare program provided hospital care for about 43 million persons,
36 million aged and 7 million disabled persons, and total Part A benefit cost was $189.0
(CMS, 2007). Medicare Part A provides the following services: in-patient hospitalization,
coverage under this part includes cost of semi-private rooms, meals, regular nursing
services, operating room services, prescription drugs, laboratory tests, psychiatric
consultations, long-term care when it is medically needed, in-patient rehabilitation, and
X-ray services. Deductibles and copayments are required under the Part A Medicare
program. Additional services under part A include skilled nursing facility services. Under
this part, care is given only if it is within 30 days of a hospitalization and required for 3
days or more. Coverage is the same as defined under in-patient hospitalization, the
number of days under this part is limited to 21-100 days, and copayment is required. Part
A does not pay for skilled nursing services if patients do not fall under skilled services
and skilled rehabilitation. Hospice and home health agency are covered under Part A
Medicare. Part B Medicare Services provides some limited services and supplies,
including diagnosis, laboratory and X-ray services ,home healthcare not covered by Part
A, preventive and screening services, physical and occupational services, speech
pathology services, radiation therapy, dialysis services, and transplant services. Also
included are rural health clinic services and ambulance services. For persons enrolled in
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Part A and Part B Medicare programs, the new Part D Medicare program provides a
prescription insurance benefit for most FDA-approved prescription drugs.
Medicare is Different from Medicaid
Medicare and Medicaid are both under federal funding. Medicare is an insurance
program that is sponsored in part by the federal government and through premiums paid
by those who are enrolled in the program. The Medicare program is run by the
Department of Health and Human Services through contracted fiscal intermediaries
called the Center for Medicare and Medicaid Services (CMS, 2012). Because Medicare is
a national program, coverage from state to state does not vary. Also, as an entitlement
program, every American that meets the age and disability requirements qualifies.
Medicaid on the other hand is designed as a means–tested program: certain criteria must
be met before eligibility, such as household income, resources, and asset level (CMS,
2012).
Medicaid is a joint partnership between the federal government and the states,
with 57% of program funding coming from the federal government, and 43% from the
states. Because Medicaid is an entitlement program, states cannot limit the number of
persons who are covered so long as those individuals meet established guidelines for
coverage. According to CMS (2012), North Carolina has about 1.8 million individuals
enrolled in the Medicaid program. This represents 19.5% of the total North Carolina
population. Reports from the state of North Carolina revealed it cost the state about
$6,424 for each single enrollee. With increased enrollment in the future for 766,200
individuals, total costs could run to $4.9 billion. Recent cuts to Medicare and Medicaid
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benefits may prevent these two key public programs from meeting their obligations, so
some cost containment strategies is necessary for the state of North Carolina.
Nursing homes play an important role in the delivery of healthcare services,
particularly to the elderly who lack the ability to care for themselves. Most of this
vulnerable population is on a low fixed income, suffers from multiple chronic conditions,
and depends on Medicare and Medicaid to help pay for health services including
prescription drugs. However, the cuts imposed by CMS in 2011 will significantly impede
nursing home facilities from delivering quality care. Medicaid covers nursing home
services, and Medicare through Part D provides for prescription drug benefits, but the
reduction enacted by CMS will exacerbate existing Medicaid shortfalls. Medicare
payments are important because they help nursing homes to cover cost of care for
Medicaid-funded patients, thus helping nursing homes to remain viable. With the
increases in chronic conditions for the elderly and the aging of in the baby boomer
generation, the need for nursing homes will increase. Unless policy makers look for ways
to address current Medicare and Medicaid cost-reduction issues, there will not be enough
nursing home facilities available to accommodate the baby boomer generation.
Drug Approval Process
The Food and Drug Administration (FDA) is an agency within the U.S.
government that regulates the nation’s food and drug supply. In 1938, Congress passed
the Food, Drug, and Cosmetic Act as a result of 107 deaths from Elixir Sulfanilamide, a
then-legal compound that contained diethylene glycol (Peters et al., 2009). The law that
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was passed in 1938 gave the FDA the authority to require evidence of drug and food
safety before allowing them to be sold to the consuming public.
It is worth recapping a brief timeline concerning the history of the generic drug
approval process. In 1968, a Drug Efficacy Conference was convened through the
National Academy of Science/National Research Council to oversee all drugs approved
between 1938 and 1962 for drug safety. The agency gave drug companies a 2-year grace
period to provide supportive evidence of drug effectiveness (Peters et al., 2009). In 1984,
the Hatch-Waxman Act (Drug Price Competition and Patent Term Restoration Act) was
passed by Congress. The act allowed the FDA to approve the manufacture of generic
drugs without requiring repetition of the research conducted by the original innovator to
prove drug safety and efficacy. The same act also allows for patent extensions and
exclusivities to innovators’ drug firms.
The goal of the Hatch-Waxman Act was to introduce generic medication that is
equivalent to brand-name drugs, but costs far less when compared to brand-name drugs.
Before being approved, new drugs must meet certain standards set forth by the FDA The
manufacturer must provide evidence after a rigorous process that the drug is safe and
effective, and after the patents expire, other companies interested in manufacturing the
generic form of the original drug can do so under the guidance of the FDA (Peters et al.,
2009). For a generic medication to be considered a substitute for a brand-name drug, the
FDA requires that certain applicable guidelines be meet, including that the generic drug
must have the same clinical effect and safety profile when given to patients under the
conditions outlined on the label. The generic drug must also prove as safe and effective as
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the brand-name drug, it must be pharmaceutically equivalent and bioequivalent, and it
must be produced in accordance with current manufacturing best-practice regulations.
Brand-name versus generic drug. A brand-name drug by definition is a
medication or medicine that is researched, developed, and marketed by a pharmaceutical
company and sold under an exclusive patent-protected brand name. When the new
medication is discovered, the company that first discovered the drug files for a patent.
This process prevents other drug manufacturers from copying and selling the new drug
(FDA, 2013). A drug has two names: the generic drug name is the common scientific
name; the other name is the brand name of the drug. This name makes the drug stand out
in the marketplace. This is true for both prescription medications and over-counter
medications. A commonplace example of this is the pain killer sold under the brand name
of Tylenol: the generic name is acetaminophen.
The FDA approves the manufacture and distribution of a generic drug because it
has the same active ingredients as its brand-name drug counterpart. Usually generic
medication is available to the public when the patent expires (patents normally last for 20
years for most drugs). When the patent expires, the original drug developer may decide to
make the generic form of the original medicine, or other drug manufacturers may decide
to make the generic version of the original drug (FDA, 2013).
Generic medication has some similarities and differences when compared to
brand-name medications. The FDA requires that to substitute generic drug for brand
name drug, the generic version must contain the same active ingredients contained in the
brand-name drug, it must have the same dosage strength, it must also have the same
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dosage form (e.g., liquid or pill form), and finally the generic drug must deliver the same
amount of drug to the bloodstream within the same time period (FDA, 2013). Federal law
requires that generic drugs have different sizes, shapes, and color markings, may have
different inactive ingredients. Generic medications are developed and manufactured by
different drug manufacturing industries and cost far less when compared to brand-name
drugs. It has been reported that generic drugs can cost between 20- and 80% less when
compared to their brand-name counterparts (FDA, 2013).
Cost difference between brand-name and generic drug. It takes several years
before new medications reach the consuming public. Research, clinical studies,
advertising, and manufacture of a new medication is costly. Generic versions of the same
drug do not have the development and research cost, and as a result generic medication
cost less than brand-name medications (CBO, 2010). The issue of not prescribing generic
medication automatically has been a concern for many, particularly with so much cost
difference. Generic medications are barred under patent provisions for up to 20 years for
most drugs (FDA, 2013).
Considering brand-name versus generic drugs is critical in managing the critically
or chronic ill patient because the cost of prescription drugs is high, Medicare and
Medicaid are having difficulty meeting their obligations because of skyrocketing
healthcare costs, and many in society cannot afford prescription drugs. Educating the
public as to the benefits of generic drugs and encouraging prescribing physicians to
consider generic drugs is critical in creating a better quality healthcare system.
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Prescription drug cost. The cost of prescription drugs has been a major concern
for many, but especially so for the elderly, healthcare organizations, and policy makers.
For example, the overall cost of prescription drugs in the US reached $307 billion in
2010, according to the CBO, an increase of $135 billion since the year 2001. This
expenditure comprised about 12% of all healthcare spending in the US. The rise in the
cost of diabetes medication, the increase in chronic health conditions, the delays in
issuing generic drugs due to patent laws, and the costs of brand-name medications are
among some of the drivers of prescription drug cost.
Generic medication is available to the drug consuming public at the expiration of
the original patent covering a brand-name drug. Yet, doctors do not prescribe generic
drugs as often as they do brand-name medications. This may be because of lack of
knowledge bout generics, insufficient time to research the availability of newer generic
drugs and what costs less, and the fact that physicians have different drug experiences
and belief systems concerning drug efficacy. Medical insurance dictates and personnel
preferences also play key roles.
A generic drug is a pharmaceutical product intended to be interchangeable with a
brand-name product that is manufactured without a license from the drug’s originating
company and marketed after the expiry date of the drug’s patent or other exclusive rights.
Generic drugs are marketed under a non-proprietary or approved name rather than a
proprietary brand name. Generic drugs are usually as effective as, but much cheaper than,
brand-name drugs. For example, paracetamol is a chemical ingredient found in brandname painkillers, but is also sold as a generic drug. Because of their low price, generic
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drugs are often the only prescription drug that the non-wealthy can access. The TradeRelated Aspects of Intellectual Property Rights (TRIPS) agreement does not prevent
governments from requiring accurate labeling or allowing generic substitution. It is
argued that competition between drug companies and generic producers has been more
effective than negotiations with drug companies in reducing the cost of drugs. The price
of the average generic drug is 75% cheaper than the retail price of the equivalent brandname prescription drug (CBO, 2010).
The cost of prescription drugs totaled $100 billion in 1999, and it is considered
the fastest growing part of personal health expenditure, the most affected is the 13 million
US population that are under Medicare benefit who do not have insurance medication
after hospitalization (Korn et al., 2003). The elderly have also seen cost of prescription
drug jump, going from $28.50 in 1992 to $42.30 in 2000 and is still increasing as a result
of the cost of prescription drugs and the number of prescriptions being written (Korn et
al., 2003). Haas et al. (2005) reported that in 2001 the national expenditure for
prescription drugs was $141 billion. Another study conducted by Holahan and Cohen
(2006) revealed that spending on prescription drugs is among the fastest growing public
programs in recent years, and recent trends have seen an average growth of 16% in
Medicaid spending between 2000 and 2004. This growth put state Medicaid program
prescription cost at $30 billion per year. Holahan and Cohen’s 2006 study also found that
in 1990, Medicaid expenditures were 7%, but it has risen to more than 14% in recent
years.
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Prescription drug costs impact every segment of society. For example Gellad,
Huskamp, Phillips, and Haas (2012) reported that the out-of-pocket cost of prescription
drugs is a serious concern for racial and ethnic minorities, as well as for the near poor,
including seniors with chronic conditions. On January 1, 2006, the Medicare Prescription
drug benefit (Part D) became law. The intention of the program was to expand drug
benefit coverage for the elderly population, including those in nursing homes with
chronic conditions.
Reports from the National Health Expenditure Accounts (NHEA) revealed that
healthcare spending reached $2.6 trillion in 2010. This is about $8,402 per person, and
represents about 18% of the U.S. GDP, (CMS, 2012).The U.S. government financed 29%
of healthcare costs in 2010, (an increase from 23% in 2007), and state and local
government paid another 16%. Further analysis from NHEA report indicates that
average yearly healthcare cost is expected to grow by 6.2% through 2018, a number that
surpasses the anticipated overall economic growth of 4.1 for the same period, and by
2018 it is reported that national healthcare spending will reach $4.4 trillion (CMS, 2012).
At this growth rate, in 15 years healthcare cost will amount to 50% of U.S. GDP. The
question becomes whether or not the U.S. economy is sustainable with this level of
expenditure.
Prescription drugs are often dispensed in hospitals and long-term care facilities
for the management of chronic diseases. It is reported that the price of the average
generic drug is 75% less than the retail price an equivalent brand-name prescription drug
(CBO, 2010).
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There are several drivers that contribute to the nation healthcare cost, the driver’s
includes chronic health condition such as diabetes, the growing elderly population, and
prescription drug cost. It is reported that prescription drug spending in the U.S reached
$307 billion in 2010, this is an increased from $135 billion in 2001, this figure comprises
of all healthcare spending of 12% (IMS Health, 2011). In the early 2000s, cost of drug
was among the fastest growing driver of healthcare spending but this spending declined
as a result of greater generic medication availability and the expiration of patents.
Generic drug is therapeutic and serve the same purpose as brand name drug and cost less
when compared to brand name drug (CBO, 2010).
Several studies conducted on generic prescription drugs have shown conclusively
that the use of cheaper generics are a critical part of what will hold down the growth of
healthcare cost both nationally and across institutional settings such as hospitals and
long-term care facilities. Studies also show that the use of generic drugs saved the U.S.
healthcare system about $1.07 trillion from 2002 through 2011, with $192.8 billion in
savings in 2011 alone (CMS, 2012). Knowing that the U.S. government share of
healthcare spending will soon reach 30%, and as the oldest baby boomers become
eligible for government-sponsored program such as Medicare, increased use of generic
prescription drugs is critical in bending the curve of Medicare and Medicaid
sustainability.
This literature review identified cost-saving approaches from various studies.
Some researchers looked at estimates that result because of the use of generic drug,
others looked at generic substitution, while still others focused on both generic and
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therapeutic substitutions. Additionally, other studies examined savings for the U.S.
healthcare system, and savings from program implementations (CBO, 2010; Haas et al.,
2005; Scott & O’Donnell, 2007).
Multiple studies conducted for the Generic Pharmaceutical Association (GPhA)
showed analytic estimates of the amount spent on generic drugs and brand-name drugs
for the years 1999 through 2010. The report found that generic substitution saved the
U.S. healthcare system about $1 trillion during that period, and that in 2010 alone generic
substitution saved the U.S. healthcare system more than $157 billion (GphA, 2011). The
Congressional Budget Office (CBO) in 2010 examined savings that resulted because of
the use of generic drugs in the Medicare Part D prescription drug program. Based on
claims data, the CBO found that substituting generic drugs for brand-name drugs resulted
in a cost saving of $33 billion in 2007 (CBO, 2010).
The CBO study further evaluated the additional savings from generic and
therapeutic substitution, and found that an increase in generic substitution rate of 100%
would have resulted in cost savings $900 billion for generic use and additional cost
savings of $4 billion for therapeutic substitutions in 2007 (CBO, 2010). Another study
analyzed cost savings through program implementation in a managed-care organization
in the form of physician participation in 2005 and 2006 of those that did not participate,
the study found that after program cost the organization saved $397, 486 in 2005 and
$453,545 in 2006 (Scott & O’Donnel, 2007). Yet another study used Department of
Veterans Affairs (VA) data to examine policy implementation in a VA hospital to
promote the use of a generic antidepressant over the brand-name drug. The researchers
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found that from March of 2002 through August, the policy resulted in a savings of $2.5
billion (Dobscha et al., 2007).
Two particular studies used claims data from 45 private health insurance
organization plans from 2003 through 2007 to compare the cost of health care in
individuals using SSRIs when mid-treatment occur in therapeutic substitution. The study
found that patients who switched from brand-name drugs to generic drugs had higher
hospitalization because of switching from brand name drug to generic drug in
midtreatment, the switched also result in generic use of healthcare cost of $881 dollars
(Wu et al., 2011). A similar study conducted by Viahiotis et al. (2011) reached a
different conclusion: their study used claim data from 2005 to 2007and compared the
healthcare costs of using brand-name drug versus generic drugs in mid-treatment for 6
months. Their conclusion was that the cost of generic antidepressant SSRIs was
significantly lower when compared to brand-name medications—the average costs were
$3,660 and $4,587 respectively.
The projected cost of the Medicare Part D prescription drug program is estimated
to reach $700 billion for 2006 through 2015. Despite the promise of extended coverage,
the very nature of the program may require additional out-of-pocket payments from those
that the program is supposed to help, particularly with respect to the gap in coverage
known as “the doughnut hole” (Gellad et al., 2012). Gellad et al. (2012) examined data
from 1996 through 2000 from the Medical Expenditure Panel Survey Household
Component (MEPS-HC), and concluded that the prescription drug Part D program as
designed did not provide all drug coverage for racial and ethnic minorities or the near
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poor, including seniors with chronic conditions. The rise of prescription drug costs is a
central policy issue for both Medicare and Medicaid programs. The incidence of chronic
health conditions is on the rise, the elderly population is growing, and prescription drug
costs are also high. According to the U.S. Census Bureau (2002), the baby boomer
generation age over 75 populations will increase from 5.8% in 1997 to 9.4% in 2025. It is
also reported by the same agency that because of advances in medical science, those with
chronic conditions are living longer; however, there will be a lack of social support
including adequate appropriate housing. Thus, increasing the number of nursing home
facilities is critical.
Currently, many states are concerned about the increase in prescription drug costs
in nursing homes because of aggressive cuts to state Medicaid programs. Second, newer
drugs have been developed to help the management of many chronic conditions, but these
newer drugs are expensive. Finally, nurses and other health professionals are concerned
about the increased use of pharmaceuticals in nursing homes. According to Mendelson et
al. (2002), an individual in a nursing homes receives an average of 6.7 routine
medications per day, with an additional 2.7 as needed medication per day. Nursing homes
are financed by three payment systems: Medicare, Medicaid, and private sources (this
includes personal funds and long-term care insurance).
Recent cuts in two major social programs will impact the way nursing homes are
financed. For example, the prescription drug benefit under Medicare Part D is designed to
help with the costs, but the structural design of the program can require additional out-ofpocket payment for those it is designed for (Hass et al., 2012). Gu, Zeng, Patel, and
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Tripoli (2010) in their retrospective study of Medicare Part D of 12,881 diabetes patients
age 65 concluded that the coverage gap—the so-called “donut hole” in Medicare Part
D—had a negative impact on diabetes medication adherence. A similar study conducted
by Piette et al. (2004) concerning out-of-pocket costs of diabetes reported that out-ofpocket cost is a significant burden to many older adults with diabetes. Their study further
revealed that diabetes patients in that study under-use their medication because of out-ofpocket cost. Several studies revealed that lack of medication compliance may lead to
further declines in health, poor quality of care, and for diabetes patient glycemic control
is almost impossible without adherence to their drug regimen.
One of the contributing factors of healthcare cost is medication noncompliance.
Piette et al. (2004) reported that older adults who suffer from diabetes do not adhere to
their medication regimen due to out-of-pocket cost, and lack of medication adherence
may lead to noncompliance. A study conducted by Mahoney, Ansell, Fleming, and
Butterworth (2008) concluded that medication noncompliance results in 125,000 annual
deaths, and accounts for 10- to 25% of all hospital and nursing home admissions. Klein et
al. (2004) conducted a cross-sectional study of a national sample of 6,535 elderly people,
and concluded that the elderly delay refilling their prescription drugs as a result of high
prescription drug cost. Felland and Reschovsky (2009) found that drug affordability
continued to be a major concern, not only within the adult U.S. population but also
among children, and some working-class Americans cannot afford their prescription
drugs due to cost. That study also found that in 2007, one in seven Americans under the
age of 65 did not fill their prescription (by comparison, in 2003 that figure was one in
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10). Their study also revealed that the most vulnerable are those with low incomes, the
uninsured, and the individuals suffering from chronic conditions.
Generic drugs are not different from brand-name drug. The cost of
prescription drugs has been a major concern for many, including the elderly, healthcare
organizations, and policy makers. For example, the total cost of prescription drugs in the
U.S. reached $307 billion in 2010, according to the CBO, an increase of $135 billion
since the year 2001. It has been reported that generic medications are equivalent to brandname drugs in terms of efficacy, and generic drugs cost far less. Generic medication
usually becomes available to the public upon the expiration of the brand-name drug’s
patent (FDA, 2013). In 1984 the Hatch-Waxman Act (Drug Price Competition and Patent
Term Restoration Act) was passed by Congress. The Act allows the FDA to approve the
manufacture of a generic drug without requiring repetition of the research conducted by
the original drug innovator to prove drug safety and efficacy. The same act also allows
for patent extensions and exclusivities to innovator drug firms. The goal of the HatchWaxman Act was to introduce generic medication that is equivalent to brand-name drugs
but costs far less when compared to the brand-name drug.
The bioequivalence of generic drugs to brand-name drugs has been documented
in several articles. For example, a study conducted by Peters et al. (2009) revealed that
generic drugs are safe, effective, and affordable when compared to brand-name drugs.
Another study conducted by Kesselheim et al. (2010) consisted of a systematic review
and meta-analysis of seizure outcomes following the use of generic versus brand-name
antiepileptic drugs. The researchers found no difference in the use of generic drugs versus
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brand-name drugs. Kesselheim et al. (2008) conducted a meta analysis to compare
generic and brand-name medications for patients suffering from cardiovascular disease.
This study concludes that the brand-name drug was not superior to the generic
medication in treating cardiovascular disease. The FDA requires that a generic drug be a
copy of a brand-name drug because it has the same dosage, safety, and strength, quality,
and performance. The FDA also requires that the only allowable differences between
generic drugs and their brand-name counterparts are shape, scoring, release method,
packaging, colors, flavors, and preservatives (FDA, 2013).
Generic drugs and cost savings. The Restoration Act of 1984 was enacted to
regulate generic drugs, and the addition of the Hatch-Waxman Act was to strike a balance
between drug innovation and cost-saving generic drug development through proper drug
approval process. The FDA requires that for a generic drug to be pharmaceutically
equivalent to a brand -name drug, it must have the same active ingredient. Several studies
have revealed that generic medication is identical to the brand-name drug counterpart
(Kesselheim et al., 2010; Peters et al., 2009).
The prevalence of chronic conditions such as diabetes is on the rise, and so is the
cost of prescription drugs. For example, the cost of prescription drugs totaled $100 billion
in 1999, and it is considered the fastest growing part of personal health expenditures.
Those most affected include the 13 million Americans who are receive Medicare benefits
who do not have insurance medication after hospitalization (Korn et al., 2003).
According to the American Diabetes Association (ADA, 2007), in 2007 there were 17.5
million people with diagnosed diabetes with an estimated cost of $174 billion in medical
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expenses and lost productivity. A similar study conducted by the ADA in 2013 that used
a prevalence-based approach reported that the economic burden for diagnosed diabetes in
the US in 2012 was $245 billion. This is a 41% increase compared to their previous
study. Proper glycemic control is critical in the management of Type 2 diabetes.
Currently there are several medications on the market to accomplish this objective;
however, prescription drug prices continue to increase. Diabetes is common in nursing
home facilities and among the elderly population, but recent cuts in Medicare and
Medicaid benefits mean that some elderly patients have not been able to afford their
prescription drug because of cost. This may negatively impact effective diabetes
management.
The use of generic drugs as a cost-saving alternative to brand-name drugs has
been supported by several research articles. Shank, Choudhry, Liberman, and Brennan
(2011) conducted a study to compare the importance of controlling blood pressure in
non-diabetic patients. Their study concluded that previous studies found that the use of
brand-name drugs cost an estimated $52,983 per quality-adjusted year life, but their study
found that by using generic drug the cost was $7,753 per quality-adjusted year life.
According to Haas et al. (2005), substituting generic drugs for the more expensive brandname prescription drug will provide savings for the drug consuming population. Peters et
al. (2009) revealed that generic drug is safe, effective, and affordable when compared to
brand-name drugs. Fischer and Avorn (2003) conducted a study to analyze state-by-state
Medicaid prescription drug spending in 2000. They concluded that in 2000, Medicaid
payments to the states was more $20.9 billion, and of this total $4.3 billion was for brand-
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name and generic medications. Their study further revealed that they identified a
potential savings of $229 million from the use of generic prescription drug.
A report from the Congressional Budget Office revealed that in 2007 total
expenditures for the Medicare Part D prescription drug benefit was $1 billion, and total
payment for pharmacies and other plans was $60 billion. Using Part D prescription drug
data, the Congressional Budget Office (CBO, 2010) reported that dispensing generic
drugs rather than brand-name reduced prescription drug cost by $33 billion in 2007, and
that total payment to plans and pharmacies would have been $95 billion without generic
substitution.
Summary
The literature reviewed thus far revealed several relevant issues. For instance, the
literature revealed that there are several drivers that increase healthcare cost, these drivers
include the high cost of brand-name prescription drugs, the prevalence of diabetes and
other chronic health conditions, and an increasing older population as a result of the
aging of the baby boomer generation. For example, according to the American Diabetes
Association (ADA, 2007) in 2007 there were 17.5 million people with diagnosed diabetes
with an estimated price tag of $174 billion in medical costs and lost productivity. The
prevalence of chronic conditions such as diabetes is on the rise, and so is the cost of
prescription drugs. For example, the cost of prescription drugs total $100 billion in 1999,
and it is considered the fastest growing part of personal health expenditure. The
population most affected is the 13 million Americans who receive Medicare benefits but
who do not have insurance for medications after a hospitalization (Korn et al., 2003). The
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cost of prescription drugs in the US reached $307 billion in 2010, according to a CBO
report—an increase of $135 billion since the year 2001.
The cost of prescription drugs to the Medicaid program is $30 billion per year,
and in 1990 Medicaid expenditures were 7%, but has climbed over 14% in recent years.
With this amount of healthcare cost, Medicare and Medicaid will have trouble meeting
their obligations to the state nursing home healthcare delivery system. If the cost of
prescription drugs is among the contributing factors to rising healthcare cost that is
impacting public programs such as Medicare and Medicaid, and generic drugs are
therapeutically equivalent to brand-name drugs, why are physicians not automatically
prescribing generic drugs? Chapter 3 of this study will focus on methodology, and the
following areas will be discussed: research design, justification for the design, ethical
issues, data collection method, inclusion and exclusion criteria, instruments used, and
data analysis method.
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Chapter 3: Methodology
The purpose of this study was to address the behavior of primary care physicians
regarding the prescribing of generic and brand-name drugs for the treatment of chronic
conditions in the state of North Carolina. The focus of this chapter is on the description of
the research methodology that was employed for conducting this research. The ethical
considerations and the limitations posed by the selected research design are described.
Inclusion and exclusion criteria and the process of recruitment of participants are
discussed. The process of data collection and the tools used in the collection of data are
also presented with the justifications for their selection. The method used for the analysis
of data is discussed, including a discussion of the validity and reliability of the research.
Design of the Research
The design of the research provides the process through which a study is
performed. Therefore, it is imperative to select a design that facilitates the
accomplishment of the objectives of the research. A quantitative design is represented in
numbers and statistical methods. Its measurements are numerically based, while its
findings are used to test a causal hypothesis. This research design is used when the aim of
the researcher is to perform a large-scale study that involves a baseline survey or an
assessment of the needs of individuals. This research design does not require the
participation of the researcher and is autonomous because it can be replicated by any
person and the results would be the same as that of the primary researcher (Friedhoﬀ et
al., 2013). Every research design has some advantages and disadvantages, and the
selected research design also has some disadvantages. There are several advantages of
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quantitative research design, including the fact that it can be used for the collection of
large quantities of data. The results of this design are typically quantifiable because they
are considered objective. Thus, the data are believed to be quantifiable and they can be
generalized to a population that is larger. It enables the observation of changes over a
long period and aids in the development of quantitative indicators (Creswell, 2014). It
facilitates the provision of distinct, quantitative measures that can be used for proposals
and grants.
There are numerous disadvantages of a quantitative research design, including the
calculation of its results through software used for data analysis (such as SPSS), Access,
or Excel); quantitative data software might not be accessible in many countries. This
research design is time consuming because the process is lengthy and it involves the
entering, cleaning, and analysis of the data by the researcher. The duration of this process
is prolonged with a larger sample size because a large sample size includes more data that
requires more time for analysis and interpretation of the results. Furthermore, a large
sample size also requires more time for the collection of data.
Therefore, a quantitative research design was used for performing this study, as it
addressed the objectives of the research. A cross-sectional survey design was employed
because it involved the use and analysis of the data that are presented in numerical form
through the employment of statistical techniques. There are several questions that are
posed by quantitative research, including when, how much, what, how, who, how many,
and where. The quantitative research method produces data that are statistically reliable
(Creswell, 2014). This enables the researcher to develop an understanding of the
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perceptions of people regarding an issue and their practice of a specific thing. The format
of quantitative data is typically in numerical form such as ranges, ratios, and averages
(ACAPS, 2012).
A qualitative design was not selected due to the constraints posed by the length
and nature of the study. Use of this design would not have offered the integrity provided
by the unspecified phenomenon through a quantitative approach.
The cross-sectional research design is a type of descriptive design that involves
the collection of data at a specific point in time from a representative population. These
designs provide information regarding the entire population or subsets of a population
that has been selected for the research. These are descriptive studies that can be used to
describe the prevalence of an attitude in the selected group of population (Schmidt,
2008). This design is used to determine the impact of one variable on other variables.
Thus, this design is used to analyze the strengths, degree, direction, and magnitude of
associations. This design enables the emergence of hypotheses that can be further tested
through experimental and quasi-experimental design. Less cost is involved in this
research design, and there is a reduced possibility of bias. The information provided
through this research design is comprehensive, and it describes the variables and the
pattern of their distribution. This design predicts the association of variables. This design
does not necessitate waiting for observed outcomes of the research. However, there is a
possibility of selection bias in this research design because the sample is selected from a
targeted group of a population which is predefined (Sousa, Driessnack, & Mendes, 2007).
The aim of cross-sectional surveys is the determination of frequency of a characteristic in
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a population that has been defined. This attribute is present in the population at a
particular point in time. Contact is made with the participants at a fixed point in this type
of research design to collect relevant information. Classification of the participants is
then performed on the basis of this information to identify them as possessing or lacking
that attribute. In some cases, an attempt of cross-sectional is beyond the limits of
provision of information on the frequency of the characteristic of interest in the
population of study through collection of information on both the characteristic of interest
and latent risk factors. These surveys are also used to assess the attitudes, practices,
beliefs, and knowledge of a population in association with events pertaining to health.
The findings of these surveys provide an indication of the extent of a problem in a
specific population at a particular period in time. The design of apt public health
measures can also be performed through this research design (Merrill, 2013).
There are two methods of data collection: primary and secondary. Primary data
provides access to primary resources, while secondary data offer information that has
been provided by previous research. Secondary data excludes the possibility of obtaining
the results that are delivered by the first-hand sources. Primary data is useful because it
allows the researcher to collect the information directly from the participants. This
ensures that the data is presented by the actual subject and not an interpretation of the
results of the original data provided by the participants to another researcher (Little,
2013).
Considering the significance of primary data, I selected this source of data. There are
numerous methods that can be used for the collection of primary data, and those methods
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vary according to the design of the research. This study was performed through a
quantitative design, and data collection was conducted by a primary data collection
method.
Justification for the Selected Research Design
This study determined the behavior of primary care physicians regarding the
prescribing of generic and brand-name drugs for the treatment of chronic conditions in
the state of North Carolina. The design for this research was a cross-sectional design.
This design was chosen because it addressed the research question of the study regarding
the influence of brand-name drugs, the therapeutic effects of brand-name medicine, and
their popularity on physicians’ patterns of prescription of brand-name medications over
generic medications considering the relative low cost of generic drugs. Through the use
of a cross-sectional research design, it became possible to predict the factors that are
responsible for impacting the attitudes of general physicians to prescribe either brandname or generic medicine. It facilitated the evaluation of the impact of these factors over
a specific time period on the behavior of general physicians.
Ethical Considerations
It is important to consider ethics prior to the commencement of a study. Ethical
considerations are a significant aspect of research throughout a study (Burns & Grove,
2011). The ethics of a study are referred to as the tentative, reasonable, and moral aspects
of employment of data provided by other researchers in a manner that does not escort its
manipulation. This phenomenon is associated with the characteristics of conscientious
research that focuses on the strength of attentiveness and legitimate consequence that
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must be agreed upon by the researcher when performing a study. Because a quantitative
design was employed in this study, there were numerous ethical considerations involved
that needed to be addressed before the commencement of the research.
Specific Ethical Issues in the Study
An ethical approval was obtained from the Institutional Review Board to allow
the researcher to perform this study. Utilization of the information regarding the practices
of general physicians might be considered sensitive because it may enable the prediction
of the practices of GPs and the influence on the behavior of patients regarding the use of
drugs. It is important to ensure the confidentiality of the participants so that their
identities can be concealed. Therefore, the participants will be asked to accept the terms
and conditions of the survey that will be mentioned on the online survey site. The
demographic data provided by the participants will be kept strictly confidential. The
results of this research will demonstrate the attitudes of GPs regarding the prescription of
drugs, so there is a chance of professional threats being posed to the GPs participating in
the research. Additionally, HIPAA issues are also involved in this research because there
are restrictions imposed by HIPAA related to the access to patient information. This can
serve as a barrier in obtaining the information from primary care physicians regarding
their habits in prescription either the brand-name or generic drugs. Therefore, participants
will sign an informed consent document to allow sharing the healthcare information for
this study (Jacobs, 2010).
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Confidentiality of the Data
It will be guaranteed that the information obtained in this research is not utilized
for any purposes other than for this specific study. The data obtained from this research
will be kept confidential and protected by keeping all the data in a personal passwordprotected laptop to ensure that only the researcher has the access to data. Following the
completion of research, all the data will be destroyed to minimize the risk of disclosure of
any confidential data.
Limitations of the Study
There are several limitations in this study. The first limitation of this study is the
limited availability of time for conducting the research as the researcher will be required
to conduct the surveys in a predetermined period of time. Second, the sample of the study
will rely only on the population of North Carolina. Therefore, the results of this research
will be representative of only a specific region and so might not be applicable to the
entire population of the world. Thus, this study will not be able to address and determine
the factors responsible for the behavior of physicians regarding the prescription of brandname drugs over generic medicines at a global level. The sample size of the study will be
a limitation since it is too small to represent the habits of all general practitioners
regarding the prescription of generic and brand-name drugs.
Another prominent limitation of this research comes from its methods of data
collection. As mentioned above, the survey will be performed online through an online
survey site. This can cause difficulties in the analysis of the data, as it will be performed
statistically and it is a prerequisite of the statistical analysis method that the sample size
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should be large enough to provide valid results. Based on this fact, there will be a need
for further research with a larger sample size to ensure the delivery of valid results.
Inclusion and Exclusion Criteria
The inclusion criteria of a study ensures that those participants are recruited that
are the target population. In the present research the target population is physicians in
North Carolina mostly because it was convenient for the researcher to contact and
conduct survey in this specific region. Other regions were not selected for conducting the
survey because the researcher was interested in determining the prescribing practices of
general physicians in this area. The parameters of the inclusion and exclusion criteria of
the primary and secondary research are different. These variations are based on the fact
that secondary research includes the information that is not provided directly by the
participants; rather, it is representative of the data provided by the primary data of other
studies. Therefore, the inclusion criteria of this study include the characteristics of
primary research method that is based on the recruitment of target population of the
research.
The participants of this study will be included based on their relevance to the
target population of the research (i.e., they must be practicing primary care physicians in
North Carolina because the object is to determine the prescribing practices of these
physicians). The researcher will ensure that all the participants prescribe both kinds of
drugs (generic and brand-name) so that it becomes possible to determine the factors that
are involved in the practicing attitudes of primary care physicians. Both male and female
physicians will be included in the study to determine the perceptions and behaviors of
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both the genders regarding the prescription of brand-name and generic medications. This
provides an opportunity to view the differences in the prescribing practices of both
genders. This enables the collection of cumulative data. Participants would be required
to have a clinical practicing experience of at least one year.
The research question that guides this study is, “what factors influence a
physician’s pattern of prescription of brand-name medications over generic
medications?” The hypotheses is Ho: brand popularity and its therapeutic effect do
influence prescribing behavior of brand-name medications over generic medications, and
H1: brand popularity and its therapeutic effect do not influence prescribing behavior of
brand-name medications over generic medications.
Data analysis is a vital component of quantitative research. The frequently used
method for analysis of quantitative data is through statistical analysis. There are various
factors that determine the manner in which the analysis of data is performed. These
factors include number of variables that are being examined, the extent of measurement
of those variables, the utilization of the data for the purpose of inferential or descriptive
functionality, and ethical responsibilities. As a result, descriptive statistics, correlational
analysis, and multiple linear regression analysis were utilized for this study using SPSS
version 23.0. Prescribing generic drugs more frequently can reduce the cost of treatment
(the dependent variable), while independent variables are therapeutic effects, side effects,
lack of quality control, and the low cost of generic drugs.
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Sample Size and Process of Sampling
The sample size of a study is a major consideration because it is the primary
source of data. Therefore, it is essential to ensure that the size of the sample is adequate
to provide results that are valid and representative of the views and observations of the
participants. It is difficult to predetermine the size of the sample because the survey will
be performed online through an online site that allows only small samples. Therefore, the
power analysis was applied by getting the list of all practicing physicians in North
Carolina from the state Board of Examiner’s Registry. Creative Research Systems survey
software was used for calculating the sample size. It provided a total population of 22,357
physicians practicing in North Carolina, and with a confidence interval of 5, the sample
size required for this study was calculated to be approximately 378 participants. A
logistic regression analysis test of the collected data was performed.

Figure 1. Power analysis of the sample size by Creative Research Systems survey
software (2012).
There are several strategies that can be used for selecting an appropriate and
adequate sample. Types of sampling methods include non-probability and probability
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sampling. The nonprobability sampling method includes purposive sampling,
convenience sampling, and snowball sampling, while the probability sampling method
includes random sampling, stratified, and cluster sampling (Rubin & Babbie, 2009).
The sampling method used in this study is a purposive sampling method. This is
based on the fact that the aim of this study is to determine the factors that affect the
prescribing attitudes of the physicians regarding brand-name and generic drugs. The
target population of this study is primary care physicians; hence, the researcher will
ensure that a sampling method is used that assures a valid sample of the target study
group. Based on these facts, a purposive sampling method was employed to make certain
that the sample contains only the physicians that are practicing medicine in North
Carolina.
Process of Recruitment
The recruitment process of this study was performed by getting a list of all the
practicing physicians in North Carolina from the state registry. Obtaining this list allowed
gathering of the contact details of all those physicians. All the primary care physicians
were then contacted via telephone and asked to participate in the survey. Contacts were
made in alphabetical order and all the physicians were called, thus ensuring that they are
practicing medicine in North Carolina. Physicians were provided brief information about
the research and if a physician did not show interest in participating, then next physician
was contacted until a sample of 378 general physicians was recruited. Therefore, the
sampling of this study was performed through purposive sampling and all the primary
care physicians practicing in North Carolina were given the chance to participate in this
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study. Physicians were guided to the online survey site where the research was being
conducted. Participants were provided with all necessary information regarding this
research to make them aware of the purpose and aim of this study. Recruitment was
based on the desire of participants to take part in the study. All participants willing to
participate were provided a link to the online survey site and further information about
the duration of the survey.
Data Collection
Data collection in this study was performed through primary methods. Although
there are several methods of data collection in quantitative primary research, surveys are
the most common and popular method for the collection of data. This is particularly
important when information has to be gathered from large groups and it is vital to obtain
standardization. There are several ways in which a survey can be constructed. Despite the
manner in which a survey is constructed, two components are always present: questions
and responses (Fowler, 2009). There has been a change in the process of surveys from the
days of paper and pencil. Exploration of the various emerging technologies is being
performed by various evaluators in the healthcare field in order to employ these new
technologies in the process of research that has led to the use of online surveys for the
collection of data (Fielding et al., 2008).
There are numerous factors that determine the selection of an appropriate survey
method. These factors include availability of resources, complexity of the questions, and
the schedule of the project. There are several factors that make web-based surveys
attractive. Firstly, they allow direct input of the collected data into a database, thus
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reducing the time and procedures involved in the collection of data and its analysis.
Secondly, through systematic checks, it becomes possible to block out the responses that
are out of range (Chaudhuri & Stenger, 2010).
This research requires the collection of descriptive data, and surveys allow this
with ease. Limitations of time and resource availability are the constraints of this study
that can be overcome by the employment of an online survey. Therefore, an online survey
method was used in this research. It has been predicted that this method will involve
some issues regarding the quality of data. It will be difficult to determine the actual
identity of a respondent. Furthermore, it will also be difficult to determine the precision
of the survey responses. A 40% response rate will be ensured through notifications to the
participants sent prior to the initiation of the survey. Evidence suggests that online
surveys usually receive higher response rates in comparison to the traditional methods
(Burton, Civitano, & Steiner-Grossman, 2012). However, considering the possibility of
lower response rates, participants were prompted by sending online flyers to motivate
them to participate in the research. Reminders were also sent to the participants to
improve the response rates (Nair, 2013).
Instruments Used
Instruments used for the collection of data appropriate for gathering the data.
There are several instruments that are employed in the data collection process in primary
quantitative research. An online survey was used for the collection of data for this study,
via the SurveyMonkey Web site. It is Web site that allows creation of online surveys on a
wide range of subjects. The survey questionnaire was adapted from various previous
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studies such as Omojasola et al. (2012), El-Dahiyat and Kayyali (2013), and Alghasham
(2009). The questionnaire was based on both open-ended and closed-ended questions and
on the nature of the question being asked. Demographic data were obtained through a
demographic questionnaire that included name, age, and clinical practice experience of
the participants. The questions used a Likert-type scale with five possible responses:
strongly agree, agree, disagree, and strongly disagree, and neutral. The variables
included: low-cost, popularity, therapeutic effect, effectiveness, quality, preference, and
side effects. This type of questionnaire enabled me to gather the data regarding the
behaviors and attitudes of the physicians regarding the prescribing of generic and brandname drugs in their practices. The various factors that lead to this behavior were explored
and determined in a descriptive and numerical form through the utilization of this kind of
questionnaire. Thus, the researcher was able to statistically analyze the data in a concise
manner. This questionnaire allowed collecting the data in a more descriptive form that
facilitated the development of increased understanding of the topic. The questions in the
questionnaire were based on the medical home model because they determined the
association of the reduced cost of generic drugs to be related with the prescribing
practices of the physicians. The concept of the medical home model is based on the
availability and provision of medicine to all the patients depending on their needs and
financial condition. The prescribing practices of primary care physicians related to the
low cost of generic drugs can predict the application of the medical home model in the
practices of those physicians. Thus, primary care physicians are expected to prescribe
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generic drugs to patients with less financial resources, based on the demands of the
patients themselves.
Validity is referred to as the accuracy or truthfulness of the measurement as
intended. The study was performed over a short duration that facilitated the exclusion of
the influence of history and maturation. The effect of experimental mortality was not a
factor in this research as it was based on a survey instead of an experiment. The threat of
testing and instrumentation was not an issue because the questionnaire was adapted from
a previous study (Omojasola et al., 2012). Reliability is based on the consistency of the
procedures involved in the research to deliver the results. It is also associated with the
extent to which research findings can be repeated or reproduced under similar settings
(Ayodele, 2010). Cronbach’s alpha was utilized further for ensuring the reliability of the
instrument by assuring that its value was .80. Furthermore, the collection of responses
from all the respondents through the same questionnaire and the possibility of utilization
of the questionnaire elsewhere ensure the repeatability of this study. Therefore, the
findings of this research are both valid and reliable. The reliability score of the developed
questionnaire was calculated with the help of SPSS and was found to be .89 for the 10item measure. This helps determine that the samples selected were valid and the
instrument is reliable.
Analysis of the Data
Data analysis is a vital component of quantitative research. A frequently used
method for analysis of quantitative data is statistical analysis. There are various factors
that determine the manner in which the analysis of data is performed. These factors
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include the quantity of variables that are being examined, the extent of measurement of
the variables, the utilization of the data for the purpose of inferential or descriptive
functionality, and ethical responsibilities.
The data from this study was analyzed statistically. SPSS version 23.0 was
utilized for this purpose. Descriptive statistics of the responses collected from the
participants were analyzed. This method determined the percentages and frequencies for
the participants’ demographic data and prescribing practices. Statistical tests applied
included logistic regression analysis of the prescribing practices of participants. This test
was based on the dependent and independent variables of the study.
Summary
Data analysis is a vital component of quantitative research. A frequently used
method for analysis of quantitative data is statistical analysis. There are various factors
that determine the manner in which analysis of data is performed. These factors include
quantity of variables that are being examined, the extent of measurement of variables, the
utilization of the data for the purpose of inferential or descriptive functionality and ethical
responsibilities. The data of this research was analyzed statistically. Chapter 4 of this
study focuses on data analysis, participants’ demographics, analysis of the survey
responses, correlation, and regression analysis, including descriptive statistics.
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Chapter 4: Analysis and Discussion
Introduction
The purpose of this research was to explore physicians’ patterns of prescription of
brand-name drugs over generic drugs. The research question for this study was the
following: What factors influence physicians’ pattern of prescription of brand-name
medications and generic medications?
These perspectives included the responsibilities and attitudes of physicians in
their prescription patterns. North Carolina is striving to supply premium healthcare
services in a period of inadequate resources, which generated the need for increased use
of generic medications because generic medication is lower in cost compared to branded
drugs. Data were analyzed using SPSS version 23.
The intended sample size for this study was 378; however, the participants’
response rate was 40% and only 151 participants completed the research study. To help
increase the return rate so as to increase the small sample size, the following techniques
were used: survey repetitions, changing email subject lines, pipping, and e-mail
notifications. Participants were male and female. In this chapter, I describe the
participants’ demographics including age, gender, ethnicity, qualification, clinical
practice, and clinical practice setting. This is followed by a presentation of the findings
from the analysis of the questionnaire analysis, which included correlations and
regression analysis.
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Participant Demographic Characteristics
Participants from varied demographic backgrounds completed the research study
and their following characteristics are described: gender, age, education, race and
ethnicity, clinical practice, and clinical practice setting. There were 151 participants. Age
in years ranged from 20 to 47 with a mean age of 30.12 (SD = 6.25). As seen in Table 1,
67 participants were female and 87 were male, and the proportions of male were higher
than the female in this survey. According to the survey respondents, 51 respondents are
postgraduate who practice medicines, and 100 respondents have MD degree in
medicines. In the demographic data, there is one table that relate to clinical practice.
Fifty four respondents were primary physicians practices; while 97 were doing
medical practice. With respect to clinical practice setting, the chart and table illustrate
that clinical practice setting is based on office setting, as described by the 55 respondents.
On the other hand, 33 respondents; stated that hospital setting is imperative, and 63
respondents reported that long term facility is their place of practice.
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Table 1: Frequency and Percentages of Participant Demographic Characteristics
Demographic Characteristics

n

%

High School

0

3.1

Some College

0

9.2

College Graduate

0

33.8

Graduate School

0

50.8

Post Graduate

51

1.5

Master Degree in Medicine

100

1.5

Total

151

Education Level

Race & Ethnicity

African American

23

4.6

Asian/Pacific Islander

34

4.6

Hispanic

29

3.1

Caucasian

64

1.5

Other

1

1.5

Total

151

100.0

Primary Physician

54

83.1

Medical practice

97

7.7

Total

151

100.0

Hospital setting

33

4.6

Long term facility

63

35.4

Office/clinical setting

55

60.0

Total

151

100.0

Clinical Practice

Clinical Practice Setting
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Analysis of the Questionnaire
This section of the study focus on the outcome of the questionnaire that was
returned from the survey participants
Item number 1: Generic Drugs and Therapeutic Effect. The focus of the first
survey question questionnaire was on physician perception of generic drug ability to
produce a therapeutic effect. As seen in Table 2, around 59% (n = 89) of respondents
strongly agreed that generic drugs are able to produce a therapeutic effect. On the other
hand, 7.3% (n = 11) strongly disagreed that generic drugs are able to produce therapeutic
effect.
Table 2: Frequency and Percentages of Responses for Survey Question 1
Generic drugs are able to produce therapeutic effect.

n

%

Strongly Disagree

11

7.3

Disagree

13

8.6

Neutral

11

7.3

Agree

27

17.9

Strongly Agree

89

58.9

Total

151

100.0

Item Number 2: Side Effects – Generic Drugs and Branded Drugs. As seen in
Table 3, about 60% (n = 91) respondents strongly agree that generic drugs cause more
side effects than branded drugs. On the other hand, only 6.6% (n = 10) of respondents
strongly disagreed that generic drugs cause side effects.
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Table 3: Frequency and Percentages of Responses for Question 2
Generic drugs cause more side effects than brand drugs.

n

%

Strongly Disagree

10

6.6

Disagree

14

9.3

Neutral

13

8.6

Agree

23

15.2

Strongly Agree

91

60.3

Total

151

100

Item Number 3: Lack of Quality Check on Generic Drugs. About 24% (n =
36) of respondents strongly agreed that there is lack of quality check on generic drugs
(see Table 4). On the other hand, 10% (n = 15) of respondents strongly disagreed that
there is a lack of quality check on generic drugs.
Table 4: Frequency and Percentages of Responses for Question 3
There is a lack of quality check on generic drugs.

n

%

Strongly Disagree

15

10

Disagree

36

24

Neutral

17

11

Agree

47

31

Strongly Agree

36

24

Total

151

100
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Item Number 4: Low Cost Generic Drugs. As seen in Table 5, 30% (n = 45) of
respondents strongly agreed that generic drugs have low cost when compared to branded
drugs. On the other hand, 16% (n = 24) of respondents strongly disagree that cost of
generic drugs is lower than branded drugs.
Table 5: Frequency and Percentages of Responses for Question 4
Generic drugs have low-cost.

n

%

Strongly Disagree

24

16

Disagree

15

10

Neutral

4

3

Agree

63

42

Strongly Agree

45

30

Total

151

100

Item Number 5: Popularity – Generic VS Branded Drugs. According to Table
6, 23% (n = 35) of respondents agreed that generic drugs are not as popular as branded
drugs. On the other hand, 20% (n = 30) of respondents disagree that generic drugs are not
as popular as branded drugs.
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Table 6: Frequency and Percentages of Responses for Question 5
Generic drugs are not as popular as brand drugs.

n

%

Strongly Disagree

20

13

Disagree

30

20

Neutral

28

19

Agree

38

25

Strongly Agree

35

23

Total

151

100

Item Number 6: Representatives - Generic VS Branded Drugs. As seen in
Table 7, 14% (n = 21) of respondents strongly agree that representatives of branded drugs
are more convincing than the representatives of generic drugs. Conversely, 17% (n = 25)
of respondents disagree that representatives of branded drugs are more convincing than
the representatives of generic drugs.
Table 7: Frequency and Percentages of Responses for Question 6
Representatives of brand drugs are more convincing than

n

%

Strongly Disagree

25

17

Disagree

36

24

Neutral

20

13

representatives of generic drugs.
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Agree

49

32

Strongly Agree

21

14

Total

151

100

Item Number 7: Prescription of Branded Drugs. The focus of this part of the
research questionnaire is on patients preferences with respect to branded drugs. As seen
in Table 8, 17% (n = 26) of respondents strongly disagreed that patients do not prefer to
be prescribed a branded drugs. On the other hand, 35% (n = 53) respondents strongly
agreed that patients prefer to be prescribed a branded drug.
Table 8: Frequency and Percentages of Responses for Question 7
Patients prefer to be prescribed a brand drug.

n

%

Strongly Disagree

26

17

Disagree

28

19

Neutral

5

3

Agree

39

26

Strongly Agree

53

35

Total

151

100

Item Number 8: Quality - Generic VS Branded Drugs. 16 % (n = 24)
respondents strongly disagreed that generic drugs are not equal in quality as brand drugs
(see Table 9). Conversely, 28% (n = 42) of respondents strongly agreed that generic
drugs are equal in quality as brand drugs.
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Table 9: Frequency and Percentages of Responses for Question 8
Generic drugs are equal in quality as brand name

n

%

Strongly Disagree

24

16

Disagree

19

13

Neutral

23

15

Agree

43

28

Strongly Agree

42

28

Total

151

100

prescription drugs.

Item Number 9: Safety - Generic VS Branded Drugs. With respect to safety of
generic drugs, 36% (n = 55) of the respondents strongly agreed that generic drugs are
safer than branded drugs, (see Table 10). On the other hand, 14% (n = 21) of the
respondents strongly disagreed that generic drugs are safer than branded drugs.
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Table 10: Frequency and Percentages of Responses for Question 9
Generic drugs are as safe as brand name prescription

n

%

Strongly Disagree

21

14

Disagree

28

19

Neutral

4

3

Agree

43

28

Strongly Agree

55

36

Total

151

100

drugs.

Item Number 10: Inferiority - Generic Versus Branded Drugs. About 28% (n
= 43) respondents strongly agree that generic drugs are inferior in quality than branded
drug (see Table 11). On the other hand, 23% (n = 35) of respondents strongly disagree
that generic drugs are inferior to branded drugs.
Table 11: Frequency and Percentages of Responses for Question 10
Generic drugs are inferior to brand name prescription

n

%

Strongly Disagree

35

23

Disagree

24

16

Neutral

10

7

Agree

39

26

Strongly Agree

43

28

drugs.
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Total

151

100

Item Number 11: Patent Expiry of Originator/Innovator. According to 24%
(n = 35) of the respondents, generic drugs are not manufactured after the patent expiry of
originator or innovator (see Table 12). Conversely, 33% (n = 50) of the respondents
strongly agreed that generic drugs are manufactured after the patent expiry of originator
or innovator.
Table 12: Frequency and Percentages of Responses for Question 11
Generic medicines are manufactured after the patent

n

%

Strongly Disagree

19

13

Disagree

16

11

Neutral

23

15

Agree

43

28

Strongly Agree

50

33

Total

151

100

expiry of originator/innovator.

Item Number 12: Low Quality - Generic VS Branded Drugs. 21 % (n = 32) of
respondents strongly disagree that generic drugs are of low quality than branded drugs
(see Table 13). Conversely, 29% (n = 44) respondents strongly agree that generic drugs
are of low quality than branded drugs.
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Table 13: Frequency and Percentages of Responses for Question 12
Generic medicines are of low quality than brand name

n

%

Strongly Disagree

32

21

Disagree

18

12

Neutral

14

9

Agree

43

28

Strongly Agree

44

29

Total

151

100

medicines.

Item Number 13: Multinational Product VS Local Product. According to
Table 14, 32% (n = 49) of the respondents, multinational products are of better quality
than local company’s product. Conversely, 16% (n = 24) of respondents strongly disagree
that multinational products are of better quality than local company’s product.
Table 14: Frequency and Percentages of Responses for Question 13
Multinational products are of better quality than local

n

%

Strongly Disagree

24

16

Disagree

21

14

Neutral

14

9

Agree

43

28

Strongly Agree

49

32

company products.
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Total

151

100

Item Number 14: Remembrance of Brand Name Medicine. According to
Table 15, 12% (n = 18) of respondents strongly disagree that it is not easier to remember
the name of branded drugs; while, 30% (n = 45) of respondents strongly agreed that it is
easier to remember the name of branded drugs.
Table 15: Frequency and Percentages of Responses for Question 14
It is easier to remember a brand name medicine.

n

%

Strongly Disagree

18

12

Disagree

24

16

Neutral

20

13

Agree

44

29

Strongly Agree

45

30

Total

151

100

Item Number 15: Affordability - Generic VS Branded Drugs. From 151
respondents, 34% (n = 52) of respondents strongly agree that generic drugs are more
affordable as compare to branded drugs (see Table 16). On the other hand, 9% (n = 14) of
respondents strongly disagree that generic drugs are more affordable as compare to
branded drugs.
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Table 16: Frequency and Percentages of Responses for Question 15
Generic medicines are more affordable as compared to brand

n

%

Strongly Disagree

14

9

Disagree

18

12

Neutral

24

16

Agree

43

28

Strongly Agree

52

34

Total

151

100

medications.

Item Number 16: Preferences of Patients. According to Table 17, 41% (n = 62)
of respondents strongly agreed that patients mostly prefer branded drugs; while only 9%
(n = 14) of respondents strongly disagreed that patient do prefer branded drugs
Table 17: Frequency and Percentages of Responses for Question 16
Patients prefer brand medications.

n

%

Strongly Disagree

14

9

Disagree

18

12

Neutral

14

9

Agree

43

28

Strongly Agree

62

41

Total

151

100

86

Item Number 17: FDA and Brand Medications. As seen in Table 18, 26% (n =
40) of respondents strongly agreed that prescription of branded drugs is good for the
health of patients as compare to generic drugs because they are approved by the FDA.
Conversely, 16 % (n = 24) of respondents strongly disagreed that prescribing brand drugs
is good for the patient because they are approved by the FDA.
Table 18: Frequency and Percentages of Responses for Question 17
Prescribing brand medications feel safe because they are

n

%

Strongly Disagree

24

16

Disagree

28

19

Neutral

14

9

Agree

45

30

Strongly Agree

40

26

Total

151

100

approved by the FDA.

Item Number 18: Option to Choose for the Medications. According to Table
19, 32% (n = 48) of respondents, patients should be given the option to choose for the
medication that is affordable to them. Conversely, 21 % (n = 32) of respondents strongly
disagree that patients should be given the option to choose for the medication that is
affordable to them.
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Table 19: Frequency and Percentages of Responses for Question 18
Patients should be given the option to choose for the

n

%

Strongly Disagree

32

21

Disagree

24

16

Neutral

10

7

Agree

37

25

Strongly Agree

48

32

Total

151

100

medication that is affordable to them.

Item Number 19: Quality of Expensive Medications. According to Table 20,
33% (n = 50) of respondents, expensive medications are considered to be better and more
effective by the patient. Conversely, 12% of respondents state that expensive medications
are not considered to be better and more effective by the patient.
Table 20: Frequency and Percentages of Responses for Question 19
Expensive medications are considered better and more

n

%

Strongly Disagree

18

12

Disagree

16

11

Neutral

24

16

Agree

43

28

Strongly Agree

50

33

effective by the patients.
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Total

151

100

The following six questions and their relationships were further explored using
descriptive statistics, correlational analysis and multiple linear regression: (a) generic
drug are unable to produce therapeutic effects, (b) do patient prefer brand name drug to
generic drugs, (c) generic drug cause more side-effects than brand name drugs, (d)
generic drug have lower cost compare to brand drugs, and (e) more of generic prescribing
can reduce cost of treatment.
Descriptive Statistics
The descriptive statistics for these variables appear in Table 21. Responses for
generic drugs are unable to produce therapeutic effects ranged from 1 (strongly disagree)
to 5 (strongly agree) with a mean of 4.12 (SD = 1.28). This indicates that, on average,
participants agreed that generic drugs are unable to produce therapeutic effects.
Responses for do patients prefer brand name drugs to generic drugs ranged from 1
(strongly disagree) to 5 (strongly agree) with a mean of 4.13 (SD = 1.28). This indicates
that, on average, participants agreed that patients prefer brand name drugs to generic
drugs. Responses for generic drugs cause more side-effects than brand name drugs
ranged from 1 (strongly disagree) to 5 (strongly agree) with a mean of 3.61 (SD = 1.52).
This indicates that, on average, participants were neutral or agreed that generic drugs
cause more side-effects than brand name drugs. Responses for generic drugs have lower
cost compare to brand drugs ranged from 1 (strongly disagree) to 5 (strongly agree) with
a mean of 4.32 (SD = 1.26). This indicates that, on average, participants agreed that
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generic drugs have lower cost compare to brand drugs. Finally, responses for more
generic prescribing can reduce cost of treatment ranged from 1 (strongly disagree) to 5
(strongly agree) with a mean of 4.32. On average, participants agreed that more generic
prescribing can reduce cost of treatment.
Table 21: Descriptive Statistics for Primary Survey Questions (N = 151)
Survey Item

Min

Max

M

SD

Generic drugs are unable to produce therapeutic effects

1.0

5.0

4.12

1.28

Do patients prefer brand name drugs to generic drugs

1.0

5.0

4.13

1.28

Generic drugs cause more side-effects than brand name

1.0

5.0

3.61

1.52

Generic drugs have lower cost compared to brand drugs

1.0

5.0

4.32

1.26

More generic prescribing can reduce cost of treatment

1.0

5.0

3.06

1.45

drugs

Correlation
Pearson correlations were used to assess the bivariate relationships between the
five primary variables: (a) generic drugs are unable to produce therapeutic effects, (b) do
patient prefer brand name drugs to generic drugs, (c) generic drugs cause more sideeffects than brand name drugs, (d) generic drugs have lower cost compared to brand
drugs, and (e) more generic prescribing can reduce cost of treatment. It is important to
note that correlations are used to examine the relationship between only two variables at a
time. Table 22 shows correlations between the variables of interest.
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Table 22: Pearson Correlations between the Variables (N = 151)
Survey item
1. Generic drug are unable to produce therapeutic

1
r

2

3

4

5

1

effects
2. Do patients prefer brand name drug to generic drugs r

.07

1

p

.36

3. Generic drugs cause more side-effects than brand

r

.18* -.07

name drugs

p

.02

.37

4. Generic drugs have lower cost compared to brand

r

.02

-.07 -.07

drugs

p

.73

.35

.35

5. More generic prescribing can reduce cost of

r

-.01

.03

-.06 .07

treatment

p

.85

.64

.43

1

1

1

.33

Note. * indicates p < .05.

Correlations with generic drugs are unable to produce therapeutic effects. As
seen in Table 22, there was a small, positive, statistically significant correlation between
generic drugs are unable to produce therapeutic effects and generic drugs cause more
side-effects than brand name drugs (r = .18, p = .02). This indicates that as agreement
that generic drugs are unable to produce therapeutic effects increases, agreement that
generic drugs cause more side-effects than brand name drugs also increases. Generic
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drugs are unable to produce therapeutic effects was not significantly correlated with any
of the other variables.
Correlations with do patients prefer brand name drugs to generic drugs. As
seen in Table 22, there were no statistically significant correlations between do patients
prefer brand name drug to generic drugs and the other four variables.
Correlations with generic drugs cause more side-effects than brand name
drugs. As previously noted, there was a small, positive, statistically significant
correlation between generic drugs cause more side-effects than brand name drugs and
generic drugs are unable to produce therapeutic effects (r = .18, p = .02). There were no
other statistically significant correlations between generic drugs cause more side-effects
than brand name drugs and the remaining three variables (see Table 22).
Correlations with generic drug have lower cost compared to brand drugs. As
seen in Table 22, there were no statistically significant correlations between generic
drugs have lower cost compared to brand drugs and the other four variables.
Correlations with more generic prescribing can reduce cost of treatment. As
seen in Table 22, there were no statistically significant correlations between more generic
prescribing can reduce cost of treatment and the other four variables.
Regression Analysis
A simultaneous multiple linear regression analysis was used to explore the
relationship between (a) generic drug are unable to produce therapeutic effects, (b) do
patients prefer brand name drug to generic drugs, (c) generic drugs cause more sideeffects than brand name drugs, (d) generic drugs have lower cost compare to brand drugs
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(the independent variable) and (e) more generic prescribing can reduce cost of treatment
(the dependent variable).
As seen in Table 23, the model was not statistically significant (F(4, 146) = 0.41,
p = .79) and accounted for only 1.1% of the variance in perceptions that more generic
prescribing can reduce cost of treatment.
Table 23: ANOVA for the Relationship between The Independent Variables and More of
Generic Prescribing can Reduce Cost of Treatment (The Dependent Variable)
Sum of
Model
1

Squares

df

Mean Square

F

p

3.55

4

0.88

0.41

.79

Residual

313.78

146

2.14

Total

317.33

150

Regression

The Tolerance, and the Variance Inflation Factor were examined. Per Cohen,
Aiken, and West (2004), the results indicated that multicollinearity was not an issue
given that Tolerance values were above .10 and VIF values were less than 10. Given the
lack of a statistically significant regression model, the regression coefficients in Table 24
were not interpreted. The null hypothesis that there will not be a statistically significant
predictive relationship between (a) generic drug are unable to produce therapeutic effects,
(b) do patients prefer brand name drug to generic drugs, (c) generic drugs cause more
side-effects than brand name drugs, (d) generic drugs have lower cost compare to brand
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drugs (the independent variable) and (e) more generic prescribing can reduce cost of
treatment (the dependent variable) was accepted.

Table 24: Regression Coefficients for the Relationship between The Independent
Variables and More Generic Prescribing can Reduce Cost of Treatment (The Dependent
Variable)
Model

B

Std.

β

t

p

Tol.

VIF

Error
Generic drugs are unable to produce
-.01

.09

-.01

-.12

.90

.95

1.04

.04

.09

.04

.49

.62

.97

1.02

-.05

.08

-.05

-.62

.53

.94

1.05

.09

.09

.07

.94

.34

.98

1.01

therapeutic effects
Do patients prefer brand name drugs
to generic drugs
Generic drugs cause more side-effects
than brand name drugs
Generic drugs have lower cost
compared to brand drugs

Linearity Test Summary
Based on Table 25, the Deviation from Linearity value of 1.198 was not
statistically significant (p > .05). Thus, there is a linear relationship between the variables
GENERICDRUG and PHYPRESCRIPTION.
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Table 25: Test of Linearity and Deviation from Linearity for PHYPRESCRIPTION *
GENERICDRUG
Sum of
Squares

df

Mean Square

More generic Between (Combined)

7.696

4

1.924

.907 .462

prescribing

.073

1

.073

.034 .853

7.623

3

Groups

Linearity

can reduce

Deviation

cost of

from

treatment *

Linearity

Generic
drugs are

Within Groups

309.641 146

Total

unable to
produce
therapeutic
effects

317.338 150

F

Sig.

2.541 1.198 .313

2.121
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Based on Table 26, the Deviation from Linearity value of 0.592 was not
statistically significant (p > .05). Thus, there is a linear relationship between the variables
BRANDEDDRUG and PHYPRESCRIPTION.
Table 26: Test of Linearity and Deviation from Linearity for PHYPRESCRIPTION *
BRANDEDDRUG
Sum of

Mean

Squares

df

Square

F

Sig.

(Combined)

4.266

4

1.066

.497

.738

prescribing can Groups

Linearity

.461

1

.461

.215

.644

reduce cost of

Deviation
3.805

3

1.268

.592

.622

313.072

146

2.144

317.338

150

More generic

Between

treatment * Do
patients prefer
brand name
drugs to
generic drugs

from Linearity
Within Groups
Total

96

Based on Table 27, the Deviation from Linearity value of 1.587 was not
statistically significant (p > .05). Thus, there is a linear relationship between the variables
PERCEPTION and PHYPRESCRIPTION.
Table 27: Test of Linearity and Deviation from Linearity for PHYPRESCRIPTION *
PERCEPTION
Sum of

Mean

Squares

df

Square

F

Sig.

(Combined)

11.263

4

2.816

1.343

.257

prescribing can Groups

Linearity

1.280

1

1.280

.611

.436

reduce cost of

Deviation
9.983

3

3.328

1.587

.195

306.075

146

2.096

317.338

150

More generic

Between

treatment *
Generic drugs
cause more

from Linearity
Within Groups
Total

side-effects
than brand
name drugs
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Based on Table 28, the Deviation from Linearity value of 0.320 was not
statistically significant (p > .05). Thus, there is a linear relationship between the variables
GENMEDICATION and PHYPRESCRIPTION.
Table 28: Test of Linearity and Deviation from Linearity for PHYPRESCRIPTION *
GENMEDICATION
Sum of

Mean

Squares

df

Square

F

Sig.

(Combined)

4.025

4

1.006

.469

.759

prescribing can Groups

Linearity

1.963

1

1.963

.915

.340

reduce cost of

Deviation
2.062

3

.687

.320

.811

313.313

146

2.146

317.338

150

More generic

Between

treatment *
Generic drugs
have lower cost

from Linearity
Within Groups
Total

compared to
brand drugs
.

In Tables 25 through 28, a summary of linearity test was conducted to check for
model violation, the analysis shows that there was no violation as such the model use is
appropriate for this study.
Summary
The focus of the study was to determine the primary care physicians’ perspectives
about the recommendation of generic medicines to their patients. These perspectives
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included the responsibilities and attitudes of physicians who prescribe medications to
their patients. The state of North Carolina is striving to supply premium healthcare
services in a period of inadequate resources. This generated the need for increased use of
generic medication due to its lower cost when compared to branded drugs. This chapter
included a descriptive analysis of 19 survey questions and the examination of the
bivariate and multivariate relationship between five key variables. All data were analyzed
in SPSS version 23.
Bivariate analysis using Pearson correlation showed that there was a small,
positive, statistically significant correlation between “generic drugs are unable to produce
therapeutic effects” and “generic drugs cause more side-effects than brand-name drugs”
(r = .18, p = .02). As agreement that generic drugs are unable to produce therapeutic
effects increases, agreement that generic drugs cause more side-effects than brand-name
drugs also increases. There were no other statistically significant correlations between (a)
generic drugs are unable to produce therapeutic effects, (b) do patients prefer brand-name
drugs to generic drugs, (c) generic drugs cause more side-effects than brand-name drugs,
(d) generic drugs have lower cost compared to brand-name drugs, and (e) more generic
prescribing can reduce the cost of treatment.
Multivariate analysis using multiple linear regression showed that there was not a
statistically significant predictive relationship between (a) generic drugs are unable to
produce therapeutic effects, (b) do patients prefer brand-name drug to generic drugs, (c)
generic drugs cause more side-effects than brand-name drugs, (d) generic drugs have
lower cost compared to brand-name drugs (the independent variable) and (e) more
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generic prescribing can reduce the cost of treatment (the dependent variable). As such,
the null hypothesis was accepted.
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Chapter 5: Recommendations, Implications, and Conclusion
This chapter provides discussions on recommendations, study implications, study
limitations, and conclusions of the study.
Key Recommendations
Stakeholders
Although current picture of the U.S. health-insurance market is uncertain,
enrollment can be anticipated in terms of demographics so there is a need for insurance
providers, policy makers, and other healthcare providers to look for innovative ways to
bring down the cost of prescription drugs.
Legal Framework
The state is responsible for creating reliable distribution channels that can provide
easy access to the insurance market. This can be accomplished through necessary
legislative, regulatory, and business policies, and it must comply with both state and
federal regulations. Consumers of insurance should be thoroughly informed about
services available, and must be taught in language that they understand. Finally, federal
agencies should monitor premium trends of insurance firms
Healthcare Insurance Plans
Commercial insurance plans should be prepared by marketing experts with the
help of innovative tools so that cost can be decreased and consumers have more choices
for selecting different providers. These innovative tools should include social media sites,
mobile applications, and print media for interacting with the consumers. Strategies should
be developed for attracting new consumers through value-added services and products
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like alternative medicines. Finally, better commercial insurance plans should include
reduced operational costs and increased consumer baselines.
Hospitals and Healthcare Professionals
Providers must manage the demands and visit resources, encourage hospitals to
provide quality healthcare at less cost through coordination. Organizational structure and
revenue analysis should be done for checking the accountability of the operations such as
collections and facilities provision records. Providers should obtain the maximum
possible information about the consumer to avoid potential bad debts, and patient
networking should be present in the insurance market
Employers
Employers should consider the incorporation of healthcare insurance as a valueadded package for their employees, should analyze the availability of better tools that
provide better potential outcomes, and provide flexibility to employees for choosing a
healthcare plan of their own choice. Finally, IT companies should obtain accurate data for
enrollment and determine ways for enhancing trends.
Consumers/Patients
Consumers must participate in insurance retailing by selecting the insurance plan
of their own choice through a better decision-making process. This can ultimately
transfer the pressure to the insurance sector for providing potential benefits within the
lowest-cost method of operations. The design of insurance plans should consider the risk
and tolerance factor for the consumer.
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Study Implications
The positive social change implication of the results of this study is such that it
would help to appropriately and optimally utilize resources by educating patients and
healthcare services providers in regard to the use of generic drugs so as to minimize cost
without compromising efficacy, and informing policy makers regarding the same.
Study Limitations
There are several limitations associated with this study. First, there was not
enough time for conducting the research as I was required to conduct the surveys in a
predetermined period of time. Second, the sample of the study only included the
population of North Carolina. Therefore, the results of this research will be representative
of only a specific region and might not be applicable to the entire population of the
United States. Sample size of the study is also a limitation because it is too small to
present the practices of all the general practitioners regarding the prescription of generic
and brand-name drugs. Another important limitation of this research was the method of
data collection. An online survey approach was used, and this method may not produce a
large enough sample size. This can cause difficulties in the analysis of the data, if such
analysis is performed statistically. Quantitative studies using the statistical analysis
method require a large sample size to provide valid results. Based on this fact, there will
be a need for further research with a larger sample size to ensure the delivery of valid
results.
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Conclusion
I concluded that in the absence of national health insurance, people are dependent
only on self-sponsored insurance and pay their expenses out of pocket. The cost is
increasing without making changes in the effectiveness of medication whether generic or
brand-name drug. Thus, it forces the healthcare professionals to exclude the insurance
benefits from the patients. The number of uninsured patients is still high and may
increase due to the high level of premium contributions. Due to increased healthcare
costs, the future growth of the sector is subjected to potential threats. Based on such
consequences, most healthcare professionals suggest generic medicines to their patients
because these drugs are cost effective.
Increased premium contributions force enrollees to switch from one plan to
another. Thus, controlling sharp swings in premiums is necessary. A law such as the
“America’s Healthy Futures Act of 2009,” although it includes insurance standards, does
not support a public healthcare plan. Furthermore, the inadequate knowledge, along with
the attitudes and perceptions of primary care physicians are minimizing the outcomes that
confuse the patients about their medication choices; for instance, generic over brandname drugs.
The standard criteria for medical interventions include assessment, classification,
planning, and education. The assessment for determining the usage can be done by
various methods by evaluating through discussion, physical evaluation, reviewing of
medication, and psychosocial as well as environmental analyses. The medication
assessment is essential for determining the effective ways of management of certain
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illnesses such as pain management in older patients. For instance, it can be done by using
an acronym such as “OPQRSTU” in which the letter “O” stands for Onset: it defines the
beginning time of pain. “P” stands for Provoking: what factors make pain conditions
better or worse. “Q” represents Quality: the feeling when the pain is occurring. “R” is for
Region/Radiation, and defines the exact location of pain. “S” indicates Severity, and it
defines the extent of the pain. “T” stands for Treatment, which establishes which
medications are currently being used, what is their effectiveness, are there any side
effects, and an examination of past medications records. The letter “U” denotes
Understanding the factors that are responsible for the pain and how the pain affects the
patient and family. “V” is for Values, and it defines the program in order to manage the
pain by considering all factors and this aspect involves a physical assessment.
The healthcare system of the United States is established on the idea that healthy
lives leads to healthy people. This is the overall strategy of the government and there is
an increasing shifting of strategies because the US is facing the key challenges of noncommunicable diseases, while sexually transmitted diseases are becoming more common
and a large portion of the population engages in alcohol consumption and smoking.
Furthermore, the mental health issue among young people and confusing conclusions
given by the doctor also create issues that sometimes results the patient’s death or loss of
function. Another bitter fact is the inequalities among poor and rich in terms of medical
treatments since 85% of the population uses public healthcare facilities, which are less
effective when the disease in question is a major threat to the life of the patient. This is
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the dilemma and it could not be solved easily just by giving health education to the
people of US (Petersen et al., 2005).
Teaching people in the US to appreciate the benefits that technology can bring for
their health is portrayed as advantageous, even although it may not prevent issues about
restrictions on the make use of ICT as “e-health” can enhance medical facilities. Health is
a major concern for the US government and broad planning gives a structure for the
improvement of the national healthcare system. The scheme gives the chance to
collectively bring the resources of the country, intercontinental expansion, commerce and
savings policies that influence the national healthcare administrative system. The
conclusion should be a scheme that is challenging and attainable, that will get better
wellbeing and welfare in the United States, and permit the government to report facts
about healthcare system (Lehrman, 2005).
The government of US should be clear about the mandate of the World Health
Organization (WHO) and other multinational agencies that can promote and encourage
healthcare systems effectively. The inputs of the domestic government and agencies
should be also countable in order to consider human rights with respect to promoting
healthcare facilities. Moreover, this should also include protection of a safe water supply
with adequate sanitary conditions in communities as well as at work places in order to
achieve good physical health. Moreover, mental health can be beneficial for the progress
of society as a whole and the population of a country (WHO, 2014).
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Appendix: Instruments
INSTRUCTIONS:
Please read and answer all questions.
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Survey Questionnaire
Part A: Perceptions about Generic and Brand name Drugs
Please place an "X" in the box to your right to the following comments below:
Strongly
Agree
Generic drugs are unable to
produce therapeutic effect?
Generic drugs cause more side
effects than Brand drugs:
There is a lack of quality check
on generic drugs:
Generic drugs have low-cost:
Generic drugs are not as popular
as brand drugs:
Representatives of brand drugs
are more convincing than
representatives of generic drugs:
Patients prefer to be prescribed a
brand drug:
Generic drugs are equal in quality
as brand name prescription drugs:
Generic drugs are as safe as brand
name prescription drugs:
Generic drugs are as effective as
brand name prescription drugs:
Generic drugs are inferior to
brand name prescription drugs:
Generic medicines are
manufactured after the patent
expiry of originator/innovator:
Generic medicines are of low
quality than brand name
medicines:
Multinational products are of
better quality than local company
products

Agree

Neutral

Disagree

Strongly
Disagree
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Please place an "X" in the box to your right to the following comments below:
Strongly
Agree

Agree

Neutral

It is easier to remember a brand
name medicine:
Knowledge about cost of
medications is low among
prescribers:
Generic medicines are more
affordable as compared to brand
medications:
Medical representativeness
influences prescribing practices:
Patients prefer brand medications:
Generic drugs generally produce
the indented therapeutic effects:
Prescribing brand medications
feel safe because they are
approved by the FDA:
Generic drug prescribing can
reduce the cost of treatment:
Patients should be asked about
their preference prior to
prescription of medication:
Patients should be given the
option to choose for the
medication that is affordable to
them:
Generic medicines should only be
prescribed on the request of
patients:
Patients prefer brand medications:
Expensive medications are
considered better and more
effective by the patients:

Part B:Demographics, Physicians
Demographics

Disagree

Strongly
Disagree
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Name:
Gender:
Age:
Race & Ethnicity:
Level of Education:
Clinical Practice:
Clinical Practice Setting:

Thank you for your time in completing this survey

